Immune memory and activation markers in systemic lupus erythematosus by LEW FEI CHUIN
1 
IMMUNE MEMORY AND ACTIVATION MARKERS IN 
















A THESIS SUBMITTED 
FOR THE DEGREE OF MASTER OF SCIENCE 
DEPARTMENT OF MICROBIOLOGY 







First of all, I would like to express my deepest gratitude to Prof David M Kemeny for being 
such a wonderful boss and supervisor for my years in Immunology Programme. Thank you 
for trusting my ability to run the flow lab, giving me tons of training opportunities to upgrade 
my knowledge (and confidence!) in flow cytometry from the scratch, and even granting me a 
chance to study part time research Master degree. I should say this is my most satisfying job 
and study experience ever. Besides, I really appreciate Hilary and your kindness, care and 
concern as friends. Looking back, I have absolutely not regretted working and studying under 
your supervision. Looking forward, I hope we will be able to keep in touch and maintain our 
friendships.  
To Dr. Paul E Hutchinson, I would really hope that we will be able to continue discussing 
about flow cytometry and chatting as friends. By sitting next to your cubicle, I learn a lot 
more about flow cytometry, about immunology, about patience, about complaining less, 
about humour etc… With you around to discuss the scientific papers, I now read much faster 
and smarter. Thank you for your guidance, I am really grateful to have you as my Flow 
Teacher. I wish Annabelle and you all the best in future undertakings and you really do not 
look like your age!! 
To Dr Paul A MacAry, Prof Ken Smith, Dr Paul Lyons, Dr Eoin McKinney and Dr 
Shaun Flint: thank you for appreciating my results and thank you for involving me in this 
wonderful project. The experience of discussing and liaising with people from Cambridge has 
enhanced my research skills and presentation skills. Special thanks to Dr Paul A MacAry 
who guided and enlightened me along the way in this study. Special dedication to Voja too, 
who helped to prepare the PBMCs and collect blood from the hospitals in this study.  
3 
I would like to extend my gratitude to the lab members of Prof Kemeny’s Lab, for always be 
there when I need assistance. To the students, Adrian, Kenneth, Sophie, Yafang, Pey Yng, 
ShuZhen, Nayana, Moyar and Isaac: you all are more than friends to me, you are just like 
my cute younger brothers and sisters, with whom I laugh, and sometimes have squabbles with. 
Special thanks to Serene and Jerina, who always try their best to make the impossible 
possible, I really appreciate your effort and time to help me. I will miss you all. 
To the bunch of my great buddies: Karwai (and Aunty Jenny), Fiona, Chientei, Hazel and 
Victoria: My life is nothing without you all. Thanks for adding colours and surprises to my 
routine and mundane life. Thanks for always lending ears to me when I need someone to 
listen to, to argue about what is right and wrong. Sorry for always updating you ladies about 
my two kids (or pregnancy) which I think it literally keeps all your mouth shut.  
To my family, thank you Dad and Keeyang. Thanks all for your support, kind understanding, 
being a great listener and giving me absolute freedom to do what I want. A deep bow to my 
Nanny Jenny who takes great care of my two beautiful angels: without the peace of mind 
you gave me, everything seemed impossible to me.  
 
Last but not least, this thesis is specially dedicated to my late Mum, Madam Ng Yu Kiat (09 
November 1947- 17 December 2010) who always wanted me to take up postgraduate studies. 
I still remember you asking me when my convocation is, sorry for not making it happen 






Table of Contents 
 
CHAPTER 1: Introduction 
1.1 General Introduction………………………………………………………………….…..18 
1.2 Innate and Adaptive Immunity………………………………………………….…....…..21 
1.2.1 Humoral Immunity………………………………………………………..……....….22 
1.2.2 Cell-mediated Immunity………………………………………………………...…...24 
1.2.3 Helper T cells………………………………………………………………..……….26 
1.3 Memory T Cells………………………………………………………………..….…......28 
1.4 Aims and Objectives……………………………………………………………...……...35 
 
CHAPTER 2: Materials and Methods 
2.1 SLE Patient Recruitment……………………………………………………….…..….…39 
2.2 Polychromatic Flow Assay Design………………………………………..….……..….. 43 
2.3 Antibody Optimization………………………………………………………..……..….. 45 
2.4 Procedures………………………………………………………………..….………..… 49 
2.4.1 Buffer Preparation…………………………………………………………...…..……. 49 
2.4.2 PBMC Preparation…………………………………………………………..…..……. 50 
2.4.3 Control Layout…………………………………………………………….….….…….51 
2.4.4 Staining Layout for Extracellular Staining………………………………….….….…...52 
2.4.5 Staining Layout for Intracellular Staining…………………………………....…..…….53 
5 
2.4.6 Staining Procedures……………………………………………………………...…..…54 
2.4.6.1 Procedure for Intracellular Staining……………………………………………...…..54 
2.4.6.2 Procedure for Extracellular Staining…………………………………………...….…54 
2.5 RNA Isolation……………………………………………………………………..……..57 
2.5.1 PBMC Separation on Ficoll Gradient……………………………………………...…..57 
2.5.2 Neutrophil Preparation………………………………………………..…………...…...59 
2.5.3 AutoMACS Cell Sorting……………………………………………..…………….…..60 
2.5.4. Cell Digestion with Qiagen QIAshredder Columns…………………………...….…...63 
 
CHAPTER 3: Results Part 1 
3.1 Antibody Optimization.......................................................................................................65 
3.2 SGH Patients’ Clinical Information...................................................................................72 
3.2.1 Prognostic Subgroup Classification................................................................................73 
3.2.2 Characteristics of Patients...............................................................................................75 
3.2.3 BILAG Scores of Patients...............................................................................................77 
3.2.4 ACR Criteria of Patients………………………………………………………...…......79 
3.2.5 Autoantibodies Found in Patients……………………………………………...…....…80 
3.2.6 Classification of Renal Biopsy in Patients………………………………….……….…81 
3.2.7 Medications Taken on Date of Blood Collection of Patients………………….….……82 
6 
3.2.8 Blood Test Results of Patients………………………………………………..……….83 
3.2.9 Discussion……………………………………………………………………………..84 
 
CHAPTER 4: Results Part 2 
4.1 T Lymphocyte Analysis  
4.1.1.1 Extracellular Staining Analysis for IL7R, CD25 and CXCR6 …….…...………88 
4.1.1.2 CD8 and CD4 T Memory Subsets………….…………..…………………..……….91 
4.1.1.3 Quantification of IL7R Expression………………………………………….………97 
4.1.1.4 Quantification of CD25 Expression……………………………….………..………100 
4.1.1.5 Quantification of CXCR6 Expression……………………………………….……..103 
 
4.1.2 Intracellular Bcl2 Analysis………………………………………………….………106 
 
4.2 Monocyte and Granulocyte Analysis……………………………………….…...…...112 
 
4.3 Plasma B and Memory B Cell Analysis ………………………………………..……117 




CHAPTER 5: Discussion  
5.1 Aims of Study...................................................................................................................125 
5.2 Discussion: Main Observations and Findings..................................................................126 
5.3 Limitations of the Study…………………………………………………………..…….130 
















Abstract   
 
Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease 
characterized by the loss of tolerance to self-antigens, immune complex deposition, tissue 
inflammation and destruction. SLE manifestations, prevalence and severity vary among 
different populations and ethnicities. Even today, the pathogenesis of SLE remains unclear. 
This complex autoimmune disease is more common in Asians (46.7/100000) than in 
Caucasians (20.7/100000). Female preponderance in SLE, especially during childbearing 
years is of an overall female: male ratio of about 9:1. With advances in SLE management via 
various therapeutic agents, the survival rate of the SLE population has increased compared to 
those of early days. But complications arising from current available treatment and therapy 
have propagated as they usually involve the use of toxic immunosuppressive drugs. More 
patients are getting serious and lethal infections due to the use of these not patient-specific 
drugs.  
 
A previous study of samples from populations of mainly European ancestry found that 
transcriptional profiling of purified CD8+ T lymphocytes identifies two distinct prognostic 
subgroups in SLE, termed v8.1 and v8.2. It was found that more subjects in group v8.1 have 
shorter time to first flare, increased flare rate, and had increased expression of IL7R and Bcl2. 
These subgroups raise the prospect of individualized therapy and suggest new potential 
therapeutic targets in SLE. The purpose of my study was to investigate these and other 
relevant biomarkers in Asian lupus patients by flow cytometry to potentially allow 
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1.1 GENERAL INTRODUCTION  
 
Systemic Lupus Erythematosus, SLE, is a chronic potentially fatal and debilitating 
autoimmune disease characterized by the loss of immune tolerance to self antigens, leading to 
the activation and expansion of autoreactive lymphocytes. The subsequent production of 
inflammatory mediators and autoantibodies ultimately causes damage to multiple organs. The 
hallmark of SLE is widespread inflammation, which may affect virtually any organ in the 
body, from skin and mucosal lesions to severe injuries in the central nervous system and 
kidney (Avihingsanon and Hirankarn 2010). Its severity in patients, mainly young women in 
their child-bearing years, can range from mild cutaneous involvement to devastating organ 
damage that can lead to death. This disease is heterogeneous; its diagnosis is easily confused 
with many other disorders. 
 
Although Lupus is normally considered a twentieth century disease, initial descriptions 
probably go as far back as thirteenth century. The physician Rogerius likened the facial rash 
and skin ulceration to the bites and scratches made by a wolf’s attack, from which some think 
lupus (Latin for wolf) derives its name. In 1948, Hargraves and colleagues discovered the LE 
cell (a neutrophil or macrophage that has phagocytized the denatured nuclear material of an 
injured cell, hematoxylin body). Although characteristic features of lupus Erythematosus are 
also found in other related connective tissue disorders.  The LE cell phenomenon was the 
specific test for the diagnosis of SLE and led to the discovery of other immunological 
markers. In 1952, immunosuppressive drugs were first introduced to treat Lupus. Derivatives 
of cortisone, prednisone, and anti-malarial drugs like plaquenil and quinacrine were 
introduced. To incorporate new immunologic knowledge and improve disease diagnostic 
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classification, the American Rheumatism Association (ARA), which has now become the 
American College of Rheumatology (ACR), established in 1982,  revised the 1971 
preliminary criteria for the classification of SLE (Passas, et al 1985) (Tan, et al 1982).  
 
The prognosis of SLE has improved over the past 4 decades, including 20-year survival rates. 
Things have gradually improved and now that SLE patients can live longer. Many patients 
manage to have a fair quality of life or are able to work full time and even have children. The 
effect of excessive active lupus disease has reduced but the complications and adverse 
reactions arising from prolonged therapy with potentially toxic drugs further aggravate these 
patients. Immunosuppressive drugs such as corticosteroid, prednisone, azathioprine, 
cyclophosphamide and sodium methotrexate are cytotoxic medications widely used in 
treating SLE. A common side effect of such drugs is immunodeficiency as the majority of 
them act non-selectively, resulting in increased susceptibility to infections and decreased 
cancer immunosurveillance. Zonana-Nacach and colleagues demonstrated that cumulative 
prednisone dose was significantly associated with osteoporotic fractures, symptomatic 
coronary artery disease and cataracts (Zonana-Nacach, et al 2000). Yet despite these 
significant advances, the scarcity of novel therapies continues. In light of this, an 
individualized therapy is needed to reduce the disease manifestations and the side effects of 
immunosuppressive drugs by the selective use.  
 
The etiology of SLE remains unknown. SLE disease activity can fluctuate greatly with most 
patients suffering disease flares alternating with prolonged durations of remission. The 
immune system is broadly compromised in patients with SLE such that deregulation of a 
single element leads to altered behavior of the whole system. Immune system molecular and 
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cellular aberrations, as well as heritable or genetic, hormonal and environmental factors 
interplay in the manifestations and presentations of the disease. 
 
All studies have shown that SLE has a particularly female preponderance, particularly in their 
childbearing years. Among children, it occurs three times more commonly in females than in 
males. Of SLE patients who experience onset of their disease between puberty and 40 years 
of age, the female to male ratio is 9:1. Only 10-15% develop the disease after age 50 when 
the female to male ratio approaches 4:1. This indicates that female hormones are likely to 
play a crucial role in the development of the disease. 
 
There is a wide disparity of lupus prevalence rate among different regions, ethnic influence 
between geographical populations further confounds patient morbidity and mortality. Studies 
performed in the UK suggest that SLE is more prevalent among Asian (40-48.8/100,000) and 
Afro-Caribbean (207/100,000) compared with Caucasian Americans or British (20/100,000). 
In addition, clinical manifestations presented vary within ethnicity. Among Asian patients, 
musculoskeletal and cutaneous involvements are the two most common features, meanwhile 
leukopenia is the most common hematologic abnormality observed. Less common 
manifestations presented are discoid rash (less than 20% of Asian patients), serositis and 
neurologic features (less than 40% of Asian patients). Renal involvement, often a cause of 
significant morbidity, is common at onset and throughout the course of disease for more than 
50% of Asian patients. Nephritis is also a concern, as it affects more than half of Asian 
patients with lupus. Nephritis is found in 10-40% of Caucasian populations (Spanish, Puerto 
Rican, European and American), meanwhile it is reported that Asian patients are 40-70% 
nephritis positive. The reported prevalence of renal disease involvement in lupus patients was 
21 
27.9% (Cervera, et al 2006) in Caucasians and 64-69.3% in Asians (Boey, et al 1988, Lee, et 
al 1993). The Asian cohort was reported to have predominantly proliferative 
glomerulonephritis on renal biopsy, leading to an increased risk of end-stage renal disease 
(Shayakul, et al 1995, Williams, et al 2003).  
 
The above statistics suggest that the Asian cohort, comparing to Caucasians, has a higher 
prevalence of major organ involvement and present more severe and lethal SLE 
manifestations. As such, we expect to see a different and more severe prognostic pattern in 
Asian cohort by using flow cytometry to investigate the T memory subsets in CD4 and CD8 
T lymphocytes.  
 
1.2 Innate and Adaptive Immunity 
SLE is a long-term autoimmune disorder, in which the immune system produces an 
inappropriate or abnormal response against its own cells, tissues and organs, resulting in 
inflammation and damage. As such, it is important to understand how the immune system 
works. The physiologic function of the immune system is to protect the body from infection. 
The system is divided into two principal branches: the innate immune system and the 
adaptive immune system. Innate immunity, also called natural or native immunity, provides 
the initial defense against infections. Based on the broad recognition of molecular patterns, it 
is nonspecific as to the type of organism it fights and is ready to be mobilized upon the first 
signs of infection. The main components of innate immunity consist of: 
a) Physical and chemical barriers such as skin, mucosal epithelia and antimicrobial 
chemicals produced at epithelial surfaces. 
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b) Blood protein, including complements and other mediators of inflammation  
c) Phagocytes (macrophages, neutrophils) and NK cells. 
d) Cytokines which regulate and coordinate activities of cells of innate immunity. 
 
In contrast to innate immunity, adaptive immunity (also called acquired immunity or specific 
immunity) develops later and involves lymphocytes and their products. It launches attacks 
specific to the invading pathogen and “remembers” antigens it has encountered and responds 
more vigorously and efficiently to repeated exposure to the same antigen. There are two types 
of adaptive immune responses, termed humoral and cell-mediated immunity.  
 
1.2.1 Humoral Immunity 
 
The humoral response begins with the activation phase, when a dendritic cell engulfs an 
extracellular antigen or microbe, by phagocytosis. Inside the cell, the new vesicle is now 
called phagosome. The phagosome then fuses with the lysosome, which contains digestive 
enzymes to degrade the endocytosed particle into fragments, in a phenomenon called antigen 
processing. Within the antigen presenting cell, the fragments then combine with class II 
MHC proteins. The complex is then displayed on the cell’s plasma membrane in the process 
known as antigen presentation. Macrophages, dendritic cells and B cells are considered 
antigen presenting cells (APC). A helper T cell (Th) participates in the next stage of the 
humoral immune response. This Th cell has T cell receptors that can bind the class II MHC 
proteins presented antigen complex. This binding triggers the APC to release IL1, which 
activates the Th cell. The activated Th cell now releases its own cytokines, which stimulate 
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the Th cell to proliferate to form a clone of Th cells, all with the same T cell receptors 
specific for the antigenic determinant of the original processed antigen.  
 
The B cell has membrane IgM receptors that are weakly specific for the same antigen as 
originally engulfed by the APC. An IgM receptor binds to the antigen and the cell engulfs the 
complex by receptor-mediated endocytosis. The B cell now behaves like an APC, processing 
and then presenting the antigen on class II MHC on the cell surface. The internalized vesicle 
fuses with a lysosome, which contains digestive enzymes. The enzymes then digest the 
antigen, processing it into fragments which are later attached to class II MHC molecules and 
displayed on the surface of the B cell. A Th cell from the clone of Th cells can now bind to 
the antigen displayed on the B cell.  The T cell receptor specifically recognizes the antigen on 
the class II MHC protein. Upon binding, the Th cell releases cytokines that stimulate the B 
cell to divide and create a clone of identical cells. Engagement of CD40 on the B cell to 
CD40L on the Th cell leads to immunoglobulin class switching.  
 
The resulting B cells develop into either long-lived memory cells or into antibody-secreting 
plasma cells. Plasma cells have an extensive endoplasmic reticulum and numerous ribosomes. 
Plasma cells are essentially antibody factories, they produce and secrete antibodies of the 
specificity identical to that of the surface receptors on the parent B cell. Like the surface IgM 
receptors on the parent B cell, the antibodies secreted by the plasma cells can bind to and 
inactivate the original antigen.  
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By the end of the humoral response, the immune system has activated specific B cells, which 
produce and release large amounts of specific antibodies. Of the millions of different B cells 
produced by the immune system, only those that can recognize the invader with the highest 
specificity survive. This specificity prevents the body from making all types of antibodies 
possible, which would very likely harm the body, in addition to being energetically costly. 
 
Antibodies defend the body in a number of ways. For example, if the antigen is a toxin or a 
virus, the binding of the antibodies to the antigens isolates the antigen, preventing them from 
contacting and harming cells of the body. Additionally, antigens which are coated with 
antibodies are easily recognized by macrophages, engulfed and digested. Antibodies also 
stimulate the complement system, which consists of a group of proteins that can 
permeabilized the cell wall of bacteria, thereby killing them and generate proinflammatory 
molecules such as C3a and C5a which are anaphylatoxins.   
 
 
1.2.2 CD8 T Cell-Mediated Immunity 
 
In the CD8 T cell-mediated immune response, immune cells kill endogenous pathogens like 
stromal cells that are cancerous or have been infected with viruses. This reaction depends on 
the lethal talents of the cytotoxic T cells (Tc). Tc cells contain perforin molecules which are 
released onto target cells and make holes in the membranes and thereby kill them. This cell-
mediated immune response occurs in two stages. In the first, called the priming phase, Tc 
cells that have specific T cell receptors are activated and triggered to proliferate repeatedly. 
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In the second stage which is called the effector phase, these activated Tc cells encounter 
target cells in the periphery and eliminate them.  
 
The cell- mediated immune response begins when an antigen, such as a virus, enters a cell. 
Note that tumor cells can also stimulate the same cellular immune sequence. During the 
infection, some of the viral proteins are degraded by the proteosomes into peptide fragments. 
These peptides are then transported to the endoplasmic reticulum (ER) by transporter 
associated with antigen processing (TAP). In the ER, the peptides are attached to class I 
Major Histocompatibility Complex (MHC) proteins, they are bound to the extracellular part 
of the class 1 MHC molecule. These complexes of antigens and class I MHC proteins are 
then inserted into the plasma membrane of cells and presented on the cell surface. A 
cytotoxic T cell (Tc) which has T cell receptors specific for the displayed antigen binds to the 
complexes of antigens and class I MHC proteins. This proliferates and forms clones of Tc 
cells, each with T cell receptors specific for the same antigenic determinant.  
 
In the effector phase, these Tc cells can now encounter and kill other infected stromal cells. 
Infected body cells present the viral antigens on their class I MHC proteins. Tc cells from the 
activation phase, each with receptors specific for the viral antigen, bind to these class 1 
MHC:peptide complexes. Upon binding, a Tc cell is activated to release perforin molecules 
which generate holes in its plasma membrane, causing the cell to lyse (Figure 1.1(a)).  
 
Naïve antigen-specific CD8+ T cells have limited recirculation pattern which does not allow 
them directly eliminate transformed or infected cells. These naïve T cells recirculate 
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throughout the secondary lymphoid compartment, migrating between lymph nodes, blood and 
spleen. To become effector cytotoxic T lymphocytes, naïve CD8+ T cells depend on 
professional Antigen Presenting Cells (APC) to capture pathogen from site of infection, 
transport them to the draining lymph nodes and scan the antigens presented by these APCs 
(which are mainly Dendritic Cells, DCs). The co-stimulatory molecules expressed by these 
DCs activate these naïve CD8+ T cells, causing them to proliferate and differentiate, and are 
then able to enter peripheral tissues to fight the invading pathogen. When APCs are not 
directly infected, they need to acquire exogenous antigens from the infectious agent and 
present them on MHC class I molecules, by a mechanism known as cross-presentation 
(Figure 1.1 (c)).  
 
1.2.3 Helper T cells  
 
Helper T cells are a subset of CD4 T lymphocytes that provide help to other effector cells 
such as B lymphocytes and cytotoxic T lymphocytes. Four types of Th cells have been 
identified so far: Th1, Th2, follicular helper T cells and Th17.  
 
Like all T cells, Th cells arise in the thymus where they express CD4 and CD8. When these 
cells lose CD8, they are called mature Th cells.  Once they are presented with both an antigen 
and appropriate cytokines, they start to proliferate and become activated (Figure1.1 (b)). 
They are dependent on the type of antigen-presenting cells, cytokines and transcription 
factors to determine which type of Th cells they become.  
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When dendritic cells, DCs, present antigen to the Th cell’s receptor and secrete IL-12, IL-18 
and IFN-γ, Th1 cells are produced. The paracrine stimulation by these cytokines causes the 
Th1 to secrete their own lymphokines like TNF-β (lymphotoxin) and IFN-γ. These 
lymphokines stimulate macrophages to kill engulfed bacteria, recruit other lymphocytes to 
the site of inflammation, and stimulate B cell class switching. Transcription factor T-bet 
plays a critical role in Th cells commitment to become Th1 as it regulates the genes needed 
for Th1 function.  
 
Th2 cells are produced when APCs present antigens to TCR with the paracrine stimulant 
interleukin 4 (IL-4). Th2 cells express GATA-3 and secrete IL-4, IL-5 and IL-13. IL-4 plays 
a major role in stimulating B cell class-switching and promotes IgE antibody production by B 
cells. IL-4 also blocks IFN-γ receptors from entering the immunological synapse on pre Th 
cells, thus preventing them from entering the Th1 pathway. Besides, IL-4 also acts as a 
positive feedback lymphokine to promote more Th cells to enter Th2 pathway. Meanwhile 
IL-5 attracts and activates Eosinophils. IL-13 recruits and activates basophils, and also 




                            
 
Figure 1.1 shows the schematic diagram of MHC class II protein presentation (a), MHC 
class I peptide presentation (b) and Cross Presentation by APCs (c). (William R. Heath 
& Francis R. Carbone 2001) 
      
 
1.3 Memory T cells 
 
Memory is the hallmark of the acquired immune system. Antigenic stimulation of naïve T 
cells is a requirement to generate memory T cells. Naïve T cells migrate to secondary 
lymphoid organs in search of antigen presented by antigen presenting cells (Butcher and 
Picker 1996). Upon exposure to a foreign antigen, primed antigen-specific T lymphocytes 
proliferate vigorously and exponentially, differentiating into effector cells which can travel to 
the inflamed tissues (Mackay 1993). The vast majority of these effector T cells undergo 
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apoptosis as the immune response progresses. They fail to survive as they fail to acquire the 
cardinal features of memory cells (Figure1.2). Expression of anti-apoptotic molecules and 
responsiveness to homeostatic cytokines are the key properties acquired progressively as the 
strength of antigenic stimulation is increased (Gett, et al 2003) . The few T cells that survive 
persist as long-lived circulating memory cells that can confer a more rapid protection upon 
secondary stimulation (Ahmed and Gray 1996, Dutton, et al 1998, Sprent and Surh 2002).   
                                
Figure 1.2 Antigenic stimulation triggers T naïve cells to proliferate and differentiate 
into effector cells. Majority of the effector T cells undergo apoptosis after the antigen 
clearance but a small proportion of them survive as long-lived T memory cells. Immunogenic 
tolerance is define as the demise of these antigen-specific memory T cells (Lakkis and Sayegh 
2003).  
 
Memory T cells have several inherent advantages over their naïve counterparts: 
 
1. The Memory T cell response to foreign antigens is faster and greater in magnitude 
than for naïve T cells (Bachmann, et al 1999, Garcia, et al 1999, Rogers, et al 2000, 
Veiga-Fernandes, et al 2000).  
2. Antigenic-specific memory T lymphocytes can persist for a lifetime in the absence of 
antigen and MHC molecules (Freitas and Rocha 1999, Goldrath and Bevan 1999, 
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Hammarlund, et al 2003, Mullbacher 1994, Murali-Krishna, et al 1999, Swain, et al 
1999).  
3. Memory T cells circulate through both secondary lymphoid tissues and peripheral 
non-lymphoid tissues (Chalasani, et al 2002, Masopust, et al 2001, Reinhardt, et al 
2001). Memory T cells can directly encounter foreign antigens and mount an immune 
response within non-lymphoid tissues. This enables them to detect and destroy foreign 
pathogens.  
 
Memory T cells are heterogeneous in terms of both their homing capacity and effector 
function. CD45 isoforms has been widely used to define naïve and memory T cells. Naïve T 
cells are held to be CD45RA positive and memory T cells to be CD45RA negative. CD62L, a 
homing receptor which is also called L-selectin, is required for cell extravasation through 
high endothelial venules (HEV) and migration to T cell areas of secondary lymphoid organs. 
In humans, co-expression of CD62L and CD45RA (marker of naïve T cells) distinguish 4 
subsets of memory T cells: T naïve (CD45RA+CD62L+), T central memory (CD45RA-
CD62L+), T effector memory (CD45RA-CD62L-) and T revertant memory 
(CD45RA+CD62L-).  
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Figure 1.3 T cell differentiation and biological space competition in CMV-specific T cell 
pool. (a)Schematic of T cell differentiation (b) Effect of vigorous CMV-specific T cell 
differentiation and accumulation of non-functional CMV-specific cells minimize the 







T revertant memory cells, which include CMV-and EBV-specific cells, are an intriguing 
subset that re-expresses CD45RA. They have higher frequencies among CD8+ than CD4+ T 
cells. Under the influence of IL-15, they can be induced to proliferate, are not an end stage 
subset and are resistant to apoptosis (Dunne, et al 2005, Dunne, et al 2002, Geginat, et al 
2003). Dunne and colleagues were the first to address the functional significance of the 
reversion of memory CD8+ T cells to the CD45RA phenotype (Dunne, et al 2005), they also 
show that these cells do not need to proliferate for effector function. Revertant T memory 
cells were found to have similar telomere length to the T cm cells, to function poorly and are 
increased in elderly subjects. Accumulation of this non-functional population reduces the 
immunological space for T cells of other specifities, which are lost through competition 
(Almanzar, et al 2005) (Figure 1.3). In elderly subjects, this population is highly 
differentiated and drives the immune pool to replicative senescence.   
 
During the secondary immune response, memory T cells proliferate and differentiate into 
effector T cells much more vigorously and rapidly than naïve T cells. Lakkis and Sayegh 
reported that upon antigenic restimulation, virus-specific CD8+ memory T cells take an 
average of 12 hours to multiply and differentiate into cytotoxic T lymphocytes, as opposed to 
several days for their naïve counterparts (Lakkis and Sayegh 2003). Furthermore, the number 
of effector T cells generated during a recall response is fivefold more than a primary immune 
response (Opferman, et al 1999). But what are the factors which cause naïve T cells to 
differentiate into either effector or memory cells upon primary antigenic stimulation?  
 
Lanzavecchia and Sallusto demonstrated that strength of antigenic and cytokine stimulation 
drives progressive T cell differentiation (Lanzavecchia and Sallusto 2002). Proliferating T 
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cells receive different levels of stimulation and thus reach different levels of differentiation 
(Figure 1.4). The magnitude of the signals that they receive is an integration of TCR, co-
stimulatory molecules and cytokine receptors signals. At increasing magnitude of antigenic 
stimulation, responding T cells gradually acquire the capacity to respond to homeostatic 
cytokines, anti-apoptotic molecules and effector functions and tissue homing receptors, 
meanwhile losing the lymph node homing marker, proliferative potential and activating their 
IL-2 producing capacity (Lanzavecchia and Sallusto 2005).  
 
After antigen clearance, activated T cells are selected for their capacity to survive in the 
presence of cytokines. Those that fail to acquire the cardinal features of memory cells which 
are defined by expression of anti-apoptotic molecules and responsiveness to homeostatic 
cytokines die by neglect. Whereas the fit cells home to appropriate tissues and survive as 
Tcm or Tem cells. 
 
Tcm home to lymph nodes and have limited effector function but upon secondary challenge 
they proliferate and become effector cells. Tcm are involved in the secondary response and 
long term protection, they might behave as memory stem cells capable of self-renewal while 
continuously generating effector cells that contribute to maintain the Tem pool (Lanzavecchia 
and Sallusto 2002). By contrast Tem are involved in immediate defense,  have limited 
proliferation capacity, home to peripheral tissues and rapidly produce effector cytokines upon 
antigenic stimulation. Newly generated memory T cells have to compete with pre-existing 
cells for survival which depends on intrinsic properties (expression of anti-apoptotic 
molecules and cytokine receptors) and available space (Di Rosa and Santoni 2003). It was 
reported that CD4+ Tem proliferate (4.7%) faster than Tcm (1.5%) and T naïve cells (0.2%) 
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(Macallan, et al 2004). This suggests that these memory T cells, particularly Tem have rapid 
turnover rate and require continuous replenishment.  
 
                            
                    
Figure 1.4 Effect of signal magnitude and antigenic stimulation signals to cell 
proliferation. (a) Different signal magnitude leading to progressive T cell differentiation. (b) 
Responses of different levels of antigenic stimulation signals which drive different levels of 






1.4 Aims and Objectives 
 
McKinney and colleagues studied two autoimmune diseases, ANCA-associated vasculitis and 
SLE in a UK population in which they identified gene-expression patterns based biomarkers 
that facilitate the clinical diagnosis of these patients. Transcriptional profiling of purified 
CD8+ T lymphocytes predicts two distinct prognostic subgroups in SLE, termed v8.1/ v4.1 
and v8.2/ 4.2 (Lyons, et al 2010, McKinney, et al 2010).  
 
It was found that subjects in the poor prognostic group v8.1/4.1 have a shorter time to first 
flare and increased flare rate per month. The subset of genes defining the poor prognostic 
group v8.1/4.1 is enriched with genes involved in IL7R pathway and TCR signaling and 
those that are expressed by memory T cells. The poor prognostic subgroup v8.1 is also 
associated with higher frequencies of T memory cells (Tcm and Tem), as shown in the Figure 
1.5. These subgroups are also found in the normal healthy population. They also had 
increased expression of IL7R and Bcl2. Bcl-2 (B-cell lymphoma 2) is defined as the founding 
member of the Bcl-2 family of apoptosis regulator proteins encoded by the BCL2 gene. IL7R 
has been shown to play a critical role in the V(D)J recombination during lymphocyte 
development (McLeod, et al 2011). This protein is also found to control the accessibility of 
the TCR gamma locus by STAT5 and histone acetylation.  
 
Patients in subgroup v8.1/4.1 may benefit from intensified maintenance therapy and follow-
up. While 75-80% of patients in v8.2/4.2 may need less maintenance therapy reducing 
treatment-associated toxicity. By identifying these subgroups as prognostic indicators, SLE patients’ 
severe manifestations could be predicted and raise the prospect of individualized toxic 
immunosuppressive therapy and may suggest new potential therapeutic targets in SLE.  
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In collaboration with Mckinney and colleagues, the purpose of my study is to investigate 
these and other relevant biomarkers in Asian lupus patients by flow cytometry to potentially 
allow individualized therapy to reduce the severe disease manifestations. Such study by flow 
cytometry as a mean to identify prognostic subgroup of SLE patients is novel and original. 
Besides investigating expression of Bcl2 and IL7R in T memory populations, expressions of 
CD25 and CXCR6 are also studied in the T memory populations of our Singapore cohort. 
Association of these prognostic groups with T regulatory cells, monocytes, neutrophils, 











                       
                           
 
Figure 1.5 Miroarray and flow cytometry data profiles of healthy and SLE cohorts.      
(a) Microarray profiles performed in Cambridge of CD8 (a) and CD4 (b) T populations for 
Singaporean (n= 136) and UK (n=718) healthy cohorts. Unsupervised hierarchical clustering 
was performed using uncentered correlation distance metric with average linkage. Red bar 
signifies prognostic group v8.1/v4.1 meanwhile blue bar means prognostic group v8.2/v4.2. It 
is clearly shown here that Singaporean cohort has a homogenous distribution of v4.1 and v4.2 
prognostic groups. Meanwhile UK cohort is more inclined to v4.2. (b) Poor prognostic group 
v8.1 is associated with higher frequencies of T memory cells (Tcm and Tem), as presented in 

































2.1 SLE Patient Recruitment  
 
Local Systemic Lupus Erythematosus (SLE) patients were recruited from two hospitals in 
Singapore: Singapore General Hospital (SGH) and National University Hospital (NUH). 
Both hospitals receive nationwide referrals from general practitioners and specialists. 
Informed consent forms were disseminated to patients, with one-to-one explanation of the 
objectives and aims of the study.  
 
Patients who fulfilled at least four of the 1997 American College of Rheumatology (ACR) 
revised criteria for the classification of SLE (Table 2.1), serially or simultaneously, during 
any interval of observation were recruited in the study. A maximum of 50ml of peripheral 
blood was collected from each patient, depending on the patient’s health conditions on the 
date of blood collection. Personal bio-data recorded include name, age, gender, ethnic group, 
date of birth, disease duration, renal biopsy classification, date of diagnosis and date of blood 
taken. Medications taken on the date of blood collection were recorded: Prednisolone, 
Azathiopine, Cyclophosphamide, Hydroxycholoquine, Methotrexate, MMF and Rituximab. 
Blood tests completed were Creatinine (Cr), C-reactive Protein (CRP) , Erythrocyte 
Sedimentation Rate (ESR), White Blood Cells (WBC), neutrophil count, lymphocyte count, 
C3 (Complement Component 3) and C4 (Complement Component 4). Presence of 
autoantibodies such as ANA (Antinuclear Antibody), anti-dsDNA (anti- double stranded 
DNA), Extractable Nuclear Antigens 4 (ENA4, which include anti-Ro, anti-La, anti-Sm and 
anti-RNP), anti-Scl-70 (Anti-topoisomerase antibodies, also referred as Anti-topo 1), anti-Jo 
1 (antinuclear antibodies directed against histidine-tRNA ligase), ACA IgM (anti-cardiolipin 
antibodies directed against IgM), ACA IgG (anti-cardiolipin antibodies directed against IgG) , 
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LAC (Lupus Anticoagulant) were included in the test too. Titres of ANA, anti-dsDNA, ACA 
IgM and ACA IgG for each patient were noted too. Clinical measure of disease activity was 
assessed using the British Isles Lupus Assessment Group (BILAG) score (Table 2.2). BILAG 
consists of 86 questions grouped under 8 headings including general, mucocutaneous, 
neurological, musculoskeletal, cardiovascular & respiratory, vasculitis, renal and 
haematological details.  
In this study, a total of 25 subjects were investigated: 19 of them were SLE patients from 
Singapore General Hospital, 3 patients from National University Hospital and the remaining 

















 Criterion  Definition  
1 Malar rash Fixed erythema, flat or raised, over the malar eminences, tending to 
spare the nasolabial folds 
2 Discoid rash Erythematous raised patches with adherent keratotic scaling and 
follicular plugging; atrophic scarring may occur in older lesions 
3 Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history 
or physician observation 
4 Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by a 
physician.  
5 Arthritis Nonerosive arthritis involving 2 or more peripheral joints, 
characterized by tenderness, swelling or effusion. 
6 Serositis  Pleuritis- convincing history of pleuritic pain or rub heard by a 
physician or evidence of pleural effusion OR Pericarditis- 
documented by ECG or rub or evidence of pericardial effusion.  
7 Renal Disorder Persistent proteinuria greater than 0.5 grams per day or greater than 
3+ if quantitation not performed. OR Cellular casts- may be red cell, 
hemoglobin, granular, tubular or mixed. 
8 Neurologic 
disorder 
Seizures- in the absence of offending drugs or known metabolic 
derangements; e.g., uremia, ketoacidosis, or electrolyte imbalance 
OR Psychosis- in the absence of offending drugs or known metabolic 
derangements, e.g., uremia, ketoacidosis, or electrolyte imbalance.  
9 Hematologic 
disorder 
Hemolytic anemia- with reticulocytosis OR Leukopenia- less than 
4000/mm
3
 total on 2 or more occasions. OR Lymphopenia- less than 
1500/mm
3
 on 2 or more occasions. OR Thrombocytopenia- less than 
100,000/mm
3
 in the absence of offending drugs.  
10 Immunologic 
disorder 
Anti-DNA: Antibody to naïve DNA in abnormal titer OR Anti-Sm: 
presence of antibody to Sm nuclear antigen OR Positive finding of 
antiphospholipid antibodies on: an abnormal serum level of IgG or 
IgM anticardiolipin antibodies.A positive test result for lupus 
anticoagulant using a standard methodA false-positive test result for 
at least 6 months confirmed by Treponema pallidum immobilization 
or fluorescent treponemal antibody absorption test  
11 Antinuclear 
antibody 
An abnormal titer of antinuclear antibody by immunofluorescence or 
an equivalent assay at any point in time and in the absence of drugs.  
 




Cat A  Denotes disease sufficiently active to merit treatment of the disease process. 
Relates to acute or progressive/ recurrent problems.  
Cat B  Denotes awareness of a potential problem. Comprises acute lesions but are less 
severe than A, or milder reversible features.  
Cat C Conditions for which symptomatic therapy would be sufficient. No indication of 
new or change in immuno-suppression.  
Cat D Indicates previous involvement of a system that has now resolved.  
Cat E Indicates the system has never been involved.  
Cat=Category  
Table 2.2 Guideline of BILAG Score  
 
Reagent  Clone  Filter  Stain Index  
PE  RPA-T4 585/40 356.3 
Alexa-Fluor 647 RPA-T4 660/20 313.1 
APC RPA-T4 660/20 279.2 
PE-Cy7 RPA-T4 780/60 278.5 
PE-Cy5 RPA-T4 695/40 222.1 
PerCP-Cy5.5 RPA-T4 695/40 92.7 
PE-Alexa Fluor 610 RPA-T4 610/20 80.4 
Alexa Fluor 488 RPA-T4 530/30 75.4 
FITC RPA-T4 530/30 68.9 
PerCP RPA-T4 695/40 64.4 
APC-Cy7 RPA-T4 780/60 42.2 
Alexa Fluor 700 RPA-T4 720/45 39.9 
Pacific Blue  RPA-T4 440/40 22.5 
AmCyan RPA-T4 525/50 20.2 
 
Table 2.3 Stain index of various fluorochrome conjugates on a BD flow cytometer. 
Courtesy from Becton Dickinson.  
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2.2 Polychromatic Flow Assay Design 
Experimental design of multicolour flow assay was prepared with a few considerations, as 
listed in the table below.  
 
No Considerations Descriptions 
1 Fluorochrome 
selection  
- Antibodies and cytokines with choice of available 
fluorochromes were matched by relative brightness 
(refer to Table 2.3). 
 
- Fluorochrome selection is instrument dependent, it 
varies with laser wavelength, laser power, filter and 
mirror sets available, optical alignment and 
pathway and PMT sensitivity. 
 
2 Relative antigen 
densities 
- The relative antigen densities could be estimated 
from the data sheet. The lowest antigen was paired 
with the brightest fluorochrome. 
 
- But this is limited by the availability of lasers, 
conjugate availability and potential spectral overlap 
considerations.  
 
3 Multiple laser 
lines optimization  
- PFC assay was optimized by using multiple laser 
lines, avoid “packing” a laser line, choosing 
optimal laser/fluorochrome combinations to 
minimize spillover background and to optimize 
signal to noise ratio. 
4 Antibody 
titration  
- Each antibody was titrated to optimize the amount 
of antibodies used. This will be elaborated in 
section 2.2. 
 
5 Background and 
negative control 
settings 
- Unstained control and single colour controls used 
were conjugated with the same fluorochromes used 
in the experiment. 
 
- They must be run at the same voltage as the 
fluorescence minus one FMO controls with the 
same cells of interest. 
 
- The purpose of running single colour controls was 
for spectral overlap compensation adjustment. 
 
- Meanwhile unstained control was meant to denote 




minus one (FMO) 
controls 
- They were included in the experimental design as 
bright single positives may change threshold levels 
between dim and background in other dimensions. 
 
- The use of autofluoroscence and isotypic controls 
is less accurate to determine threshold over 
background. 
7 Spectral overlap 
compensation  
- It was adjusted by bi-exponential compensation matrix. 
 
- Compensation percentages of each parameter were 
adjusted to achieve equal mean fluorescence value for 




      Table 2.4 Considerations of Polychromatic Flow Cytometry Assay Experimental  


















2.3 Antibody Optimization  
 
1. Viable PBMCs isolated from normal volunteer donor’s blood were counted. 
2. Cells were resuspended with wash buffer (PBS+0.1% BSA) to obtain 0.5 million 
cells/ 50ul. 
3. 0.5 million cells (=50ul) were transferred to each well of Plate 1a (Table 2.5) and 
Plate 1b, as shown in Table 2.6, (surface antibody titration), meanwhile 1 million 
cells were transferred to Plate 2, as shown in Table 2.7 (intracellular antibody 
titration) as below. Each well was topped up to 200ul with wash buffer after 
adding the cell suspension. 
4. Plates 1a, 1b and 2 were spun down at 350g for 5 minutes at 4°C. 
5. Supernatant was discarded and the plates were blotted dry. 
6. Master mix antibodies were added in dark as shown in the table for Plate 1a and 
1b below. Plates were incubated in dark for 45 minutes. 
7. As for plate 2, cells were resuspended with 200ul Fix buffer (PBS + 1% PFA). 
Cells were incubated for 20 minutes at room temperature.  
8. Plate 2 was later spun at 350g for 5 minutes at 4°C. Cells were washed twice with 
2x Permeabilization buffer (0.1% Saponin in PBS + 0.5% BSA). 
9. Cells in Plate 2 were incubated in 200ul Permeabilization buffer for 30 minutes at 
room temperature.  
10. Plate 2 was spun down at 350g for 5 minutes at 4°C. Supernatant was discarded 
and the plates were blotted dry.  
11. Master mix antibodies were added in dark as shown in the table for Plate 2 below. 
Plate 2 was incubated in dark for 45 minutes.  
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12. After incubation both plates were washed twice with buffer (wash buffer for Plate 
1a and 1b while Permeabilization buffer for Plate 2), spun down at 350g for 5 
minutes at 4°C.  
13. For all plates, supernatant was discarded and cells were resuspended with 200ul 
Fix buffer.  
14. All samples were transferred to FACS tube and analyzed with flow cytometer.  
 
Per 1 million cells 1ul 3ul 5ul 10ul 
CD62L-FITC + CD8-PB          
CD16-PB + CD13-APC         
CD138-FITC + CD38-APC          
FITC iso + APC iso          
CD3-PC7          
CD45RA-PerCpCy5.5         
CD27-APC          
     Table 2.5 Plate 1a. Table shows the surface monoclonal antibodies titration in duplicates. 
 
 
Per 1 million cells 1ul 3ul 5ul 10ul 
IL7R-PE         
CD25-PE         
CXCR6-PE         
CD14-PE          
CD19-PE         
PE iso         
         
    Table 2.6 Plate 1b. Table shows the surface monoclonal antibodies titration in duplicates. 
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Per 1 million cells 1ul 3ul 5ul 10ul 
CD62L-FITC + CD8-PB         
Foxp3-A647 + CD25-PE         
CD45RA-PerCpCy5.5         
CD4-FITC         
Bcl2-PE         
PE iso          
         
     
Table 2.7 Plate 2. Table shows the intracellular monoclonal antibodies titration in duplicates. 
 
15. Antibody master mix for each surface antibody was prepared as shown in  Table 2.8 


























well/ 1 million 
cells (ul/1 
million cells) 











 3 97 3 
 5 95 5 
 10 90 10 
    
TWO  1 98 1 
 3 94 3 
 5 90 5 
 10 80 10 
 
Table 2.8 Master mix preparation for extracellular antibody titration for Plate    1a and 1b.  
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well/ 1 million 
cells (ul/1 
million cells) 
ONE  2 98  
 
     
 







 6 94 3 
 10 90 5 
 20 80 10 
    
TWO 2 96 1 
 6 88 3 
 10 80 5 
 20 60 10 
 














2.4.1 Buffer Preparation:  
 
Intracellular Fixation and Permeabilization Buffers: 
1. Intracellular fixation and permeabilization buffers were prepared from BD Human 
FoxP3 Buffer Set (BD Pharmingen: 560098). These buffers need to be made fresh for 
each experimental set. 
2. Foxp3 Buffer A (x10 concentrated) was diluted 1:10 with room temperature deionized 
water.  
3. To make a working solution of Buffer C, FoxP3 Buffer B was diluted into 1x FoxP3 
Buffer A at a ratio of 1:50 (Buffer A: Buffer A).  
4. The buffers were brought to room temperature before use.  
 
Red Blood Cell (RBC) Lysis Buffer: 
1. FACS Lysing Solution x10 concentrated (BD: 349202) was diluted 1:10 with room 
temperature deionized water. The prepared solution is stable for a month if stored in 
glass container at room temperature.  
 
Wash Buffer:  
1. Wash buffer was prepared with 1x PBS + 0.1% BSA.  
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2.4.2 PBMC Preparation: PBMC (Peripheral blood mononuclear cells) separation on 
Ficoll Gradient  
 
1. All tubes of whole blood collected from patients were pooled into a T75 flask. 
The remaining blood in the collection tubes was rinsed with 2ml 0.4% Sodium 
citrate and added into the T75 flask.  
2. 1:1 dilution was prepared by adding 0.4% Sodium citrate into the T75 flask and it 
was mixed by shaking.  
3. 15ml of Ficoll paque was aliquoted into 50ml of BD falcon tubes. 20ml of blood 
diluted with sodium citrate from step 2 was layered slowly and gently on top of 
the Ficoll paque.  
4. The buckets of tubes were balanced before centrifugation.  
5. Tubes were centrifuged at 1900 rpm for 20 minutes at room temperature with 
acceleration: 3 and brake off.  
6. Transfer the buffy coat layer (white ring) into 50ml tubes and top up with Sodium 
citrate solution, mixed by inverting the tubes.  
7. 1st PBMC washing: sample was spun at 2000rpm for 10 minutes at room 
temperature. It is important to remove as much ficoll as possible as it can interfere 
with the RNA extraction later.  
8. Optionally, if pellet appears red, it was resuspended  in 5ml of RBC lysis buffer 
and incubated for 2 minutes. The mixture was later topped up with wash buffer 
and centrifuged at 1600 rpm for 5 minutes at 4°C.  
9. PBMCs were collected and the supernatant was discarded. The pellet was 
resuspended and tubes filled with Sodium citrate (or running buffer).  
10. 2nd PBMC washing: sample was centrifuged at 1600rpm for 5 minutes at 4°C.  
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11. Supernatant was removed and PBMCs were pulled to one tube, topped up with 
wash buffer and cells were counted.  
12. 3rd PBMC washing: step 10 was repeated. 
13. Supernatant was removed and cells were suspended in wash buffer with a 
concentration of 10million cells/ ml. 
 
 
2.4.3 Control Layout 
 
Tube  Control Antibody  
(volume in μl) 
1 FITC single CD62L (10) 
2 PE single IL7R (5) 
3 Intracellular PE single Bcl2  (10) 
4 Intracellular A647 single FoxP3 (10) 
5 PC7 single CD3 (5) 
6 PerCpCy5.5 single CD45RA  (10) 
7 APC single CD13 (10) 
8 PB single  CD8 (2.5) 
9 Unstained  None  
 
Table 2.10 Unstained and single colour controls. Each tube contains 10ul of FcR Blocking 













Cell Label FITC PC7 PerCpCy5.5 PB APC PE 
(volume in μl) 




























CD45RA (10) CD8 
(2.5) 




Mo/ Neut CD62L 
(10) 
















16 B Cells B Plasma CD138 
(10) 




17 B Memory CD62L 
(10) 












FMT: Fluorescence minus two  
 
 
Table 2.11 Staining layout for T cells, Granulocytes and B cells. Each tube contains 10ul 







2.4.5 Staining Layout: Intracellular Staining for T cells and T Regulatory cells.  
 
 
Tube Cell Label FITC PC7 PerCpCy5.5 PB AF647 PE 
   (volume in μl) 

























FoxP3  CD4 
(10) 
















--- --- --- --- PE iso 
(10) 
FMO: Fluorescence minus one 
 
Table 2.12 Staining layout for intracellular T cells and T regulatory cells. Each tube 






2.4.6 Staining Procedures 
 
2.4.6.1 Procedure for Extracellular Staining 
1. Surface marker antibodies were added to corresponding FACS tubes 
2. 100ul of whole blood was aliquoted to each tube and mixed well.  
3. Cells were incubated for 20 minutes in dark at room temperature.  
4. Samples were vortexed before 2ml of RBC lysis buffer was added to each tube.  
5. Samples were vortexed thoroughly.  
6. Cells were incubated for 10 minutes in dark at room temperature.  
7. Sample was then centrifuged at 350g for 8 minutes at room temperature.  
8. Supernatant was decanted. Pellet was then resuspended with 2ml running buffer.  
9. Step 7 was repeated to wash the cells.  
10. Supernatant was discarded. Cells were resuspended in 250ul running buffer.  
11. Samples were then stored at 4°C and analyzed within 4 hours. Cells were vortexed 
thoroughly at low speed to reduce aggregation before acquiring.  
 
 
2.4.6.2 Procedure for Intracellular Staining  
1. Surface marker antibodies were added to corresponding FACS tubes. Each tube was 
topped up to 50ul with 1x PBS. 
2. 100ul of cells (=1x 106 cells) was aliquoted to each tube and mixed well, total volume 
of the tube was 150ul at this point.  
3. Cells were incubated for 20 minutes in the dark at room temperature.  
4. 2ml wash buffer was added to each tube.  
5. Samples were centrifuged at 1000rpm for 10 minutes at 4°C.  
6. Supernatant was discarded. Pellet was resuspended in remaining volume.  
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7. 2ml of Buffer A was added and vortexed to fix the cells.  
8. Mixture was incubated in the dark for 10 minutes at room temperature.  
9. Sample was centrifuged at 2000rpm for 5 minutes at room temperature.  
10. Supernatant was discarded to remove fixative. This step needs extra care as the pellet 
is buoyant at this stage.  
11. Pellet was washed with 2ml running buffer to wash the cells.  
12. Samples were centrifuged at 2000rpm for 5 minutes at room temperature.  
13. Supernatant was discarded to remove wash buffer and pellet was resuspended gently 
in 0.5ml 1x Buffer C, in order to permeabilize the cells.  
14. Mixture was incubated for 30 minutes in the dark at room temperature.  
15. Sample was then washed with 2ml running buffer, centrifuged at 2000rpm for 5 
minutes at room temperature.  
16. Supernatant was discarded. Pellet was washed again by repeating step 14.  
17. Conjugated intracellular antibodies or isotype controls were added to corresponding 
tubes. Pellets were mixed well with the antibodies or isotype controls.  
18. Sample was incubated in dark for 30 minutes in dark at room temperature.  
19. 2ml running buffer was added, sample was then centrifuged at 2000rpm for 5 minutes.  
20. Supernatant was discarded and pellet was resuspended in 200ul of running buffer.  









 Specificity Fluorochrome Clone Source Cat No. 









CD8 Pacific Blue RPA-T8 BD 558207 
SELL(CD62L) FITC DREG-56 BD 555543 
CD45RA PerCP-Cy5.5 HI100 ebioscience 45-0458-73 
IL7R (CD127) PE HIL-7R-M21 BD 557938 
CD25 PE 143-13 Biosource AHS2517 
CD25 PE 143-13 Abcam ab16178 
CXCR6  PE  56811 R&D FAB699P 
Isotype PE MOPC-21 BD 554680 
Bcl2 PE MOPC-21 BD 556535 





CD16 Pacific Blue 3G8 BD 558122 
CD13 APC WM15 BD 557454 
CD14 PE M5E2 BD 555398 
Isotype FITC M18-254 BD 553478 






CD38 APC HIT2 BD 555462 
CD138  FITC     
CD19  PE HIB19 BD 555413 
SELL (CD62L) FITC DREG-56 BD 555543 
CD27 APC 323 eBioscience 17-0279 
Isotype FITC M18-254 BD 553478 
Isotype APC X40 BD 340442 
      





FoxP3 AF647 259D/C7 BD 560045 
CD4 FITC RPA-T4 BD 555346 
CD25 PE 143-13 Abcam ab16178 
Isotype PE MOPC-21 BD 554680 
Isotype AF647 MOPC-21 BD 557732 
Blocking Regent FcR block    Miltenyi 130-059-901 
Table 2.13 List of antibodies used in the study.  
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2.5 RNA Isolation  
This part of the work was kindly contributed by Dr Vojislav Jovanovic.  
 
2.5.1. PBMC (Peripheral blood mononuclear cells) separation on Ficoll Gradient  
1. All tubes of full blood were pooled into a T75 flask. The remaining blood in 
the collection tubes was rinsed with 2ml 0.4% Sodium citrate and added into 
the T75 flask.  
2. 50ml of 0.4% Sodium citrate was added into the T75 flask and it was mixed 
by shaking.  
3. 15ml of Ficoll paque was aliquoted into 50ml of BD falcon tubes. 20ml of 
blood diluted with sodium citrate from step 2 was layered slowly and gently 
on top of the Ficoll paque.  
4. The buckets of tubes were balance before centrifugation.  
5. Tubes were centrifuged at 1900 rpm for 20 minutes at room temperature with 
acceleration: 3 and brake off.  
6. Transfer the buffy coat layer (white ring) into 50ml tubes and top up with 
Sodium citrate, solution was mixed by inverting the tubes.  
7. 1st PBMC washing: sample was spun at 2000rpm for 10 minutes at room 
temperature. It is important to remove as much ficoll as possible as it can 
interfere with the RNA extraction later.  
8. Optionally, if pellet appears red, 5ml of RBC lysis buffer was resuspended and 
incubated for 2 minutes. The mixture was later topped up with running buffer 
and centrifuged at 1600 rpm for 5 minutes at 4°C.  
9. PBMCs were collected and supernatant was discarded. Pellet was resuspended 
and tubes were filled up with Sodium citrate (or running buffer).  
10. 2nd PBMC washing: sample was centrifuged at 1600rpm for 5 minutes at 4°C.  
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11. Supernatant was removed and PBMCs were pulled to one tube, topped up with 
running buffer and cells were counted.  
12. 3rd PBMC washing: step 10 was repeated. 
13. Supernatant was removed and cells were suspended in running buffer with a 
concentration of 10million cells/ ml.  
14. 500ul (= 5x 106) PBMCs were added respectively into a RNA and a genomic 
DNA labeled 15ml falcon tubes. Tubes were later kept on ice.  
15. 50ul (=0.5 x 106) of PBMCs were aliquoted in each of 4 single-color controls 
(APC only, FITC only, PE only and unstained control).  
16. Remaining PBMCs were divided into two 15ml falcon tubes for separation 
purposes (pre-CD14 and pre-CD19 falcon tubes).  
17. Tubes were spun at 1600 rpm for 5 minutes at room temperature.  
18. Supernatant was discarded and pellet was resuspended with the remaining 
volume.  
19. Anti-CD14 or anti-CD19 microbeads together with FCR blocking reagent 
(TCRM3) were added into each PBMC tube respectively at the concentration 
of 2ul of microbeads/ 1 million of cells.  
20. Mixture was incubated in fridge for 20 minutes on the AutoMACS.  
21. 5ml running buffer was added into each tube.  
22. Tubes were centrifuges at 1600rpm for 5 minutes at 4°C.  
23. Pellet was resuspended with 500ul running buffer.  
24. 20ul of pre-CD14or pre-CD19 was added to corresponding FACS tubes and 




2.5.2. Neutrophil Preparation (In Parallel with 2.5.1) 
 
1. From step A3, after the buffy coat was harvested, Ficoll was removed from tubes 
and RBC lysis buffer added and pellet resuspended.  
2. Mixture was incubated in fridge for 30 minutes.  
3. Sample was centrifuged at 1600rpm for 5 minutes at 4°C.  
4. Supernatant was removed, pellet was resuspended in 50ml of RBC lysis buffer.  
5. Step B3 was repeated.  
6. Supernatant was decanted and cells were pooled. Cells were resuspended in 
running buffer. Cells were counted.  
7. Step B3 was repeated.  
8. Supernatant was discarded and cells were resuspended in the remaining volume. 
Cells were kept on ice.  
9. Anti-CD16 microbeads and FCR blocking agent (TCRM3) were added into the 
sample at the concentration of 1ul microbeads/ 1 million cells.  
10. Repeat step A20-A23.  
11. 20ul of pre-CD16 was added to corresponding FACS tubes and samples were kept 









2.5.3. AutoMACS Cell Sorting 
 
PBMCs were separated to CD4+, CD8+, CD14+, CD19+ and CD16+ cells by using 
automated magnetic cell sorter from Miltenyi, AutoMACS cell sorter. These cells were later 
lysed and digested with Qiagen QIAshredder to yield RNA, which was later delivered to 
Cambridge UK for microarray gene profiling.  
 
AutoMACS Running Buffer: Optimized separation buffer from Miltenyi. It is sterile 
filtered buffer containing BSA, EDTA and 0.09% Azide.  
 
AutoMACS Rinsing Buffer:  For rinsing and cleaning cycles on AutoMACS’s fluidics 




1. Waste bottle level was checked before placing the instrument into the biosafety 
cabinet.  
2. “Running” and “Rinsing” buffer were loaded in the hood and kept on ice.  
3. A container was placed at the bottom of the nozzle and “Clean” program was run.  
4. CD16, CD19 and CD14 fractions were separated on AutoMACS.  
5. 15ml falcon tubes for positive and negative fractions were placed at the nozzle 
respectively. “Separation” button was pressed and “Possel” button was clicked too. 
“Possel” means positive selection, it allows the machine to select and keep the 
positively selected cells.  
6. Volume of the negative fraction for CD14 and CD19 was recorded.  
61 
7. Tubes with the positive and negative fractions were kept on ice.  
8. The following antibodies were added into the corresponding FACS tubes.  
- CD14+      50ul 
- CD14-       50ul 
- CD16+      50ul  
- CD16-     300ul 
- CD19+      50ul 
- CD19-       50ul  
9. “Q-rinse” was clicked. Tube was placed at the nozzle to collect liquid.  
10. Program “Sleep” was used if there was no other samples for separation.  
11. Cells were counted.  
12. CD14- and CD19- fractions were centrifuged at 1600rpm for 5 minutes at 4°C. Pellet 
was resuspended in small volume.  
13. CD14- sample was incubated with anti-CD4 microbeads. CD19- sample was 
incubated with anti-CD8 microbeads at the concentration of 2ul microbeads per 1 
million cells.  
14. Mixture was incubated in the fridge. 
15. 5ml running buffer was added to the tube and sample was centrifuged at 1600 rpm for 
5minutes at 4°C.  
16. Pellet was resuspended in 500ul of running buffer.  
17. 20ul of pre-4+ and CD8+ fractions were transferred into the FACS tubes.  
18. CD14- and CD19- were separated.  



































(TCRM3 + anti-CD14) 
CD19+/CD19- 









NUH – Immunology Programme 
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2.5.4. Cell digestion with Qiagen QIAshredder columns (after cell sorting on 
AutoMACS) 
 
1. Centrifuge all the 15ml falcon tubes:CD14+, CD19+, CD4+, CD8+, CD16+ and 
PBMCs for RNA, at 1600rpm for 5 minutes at 4°C. 
2. 4ml of RLT and 40ul of β–mercaptoethanol were added into each the tube. 
3. Supernatant was removed completely and pellet was resuspended in respective 
amount of RLT buffer mix.  
4. Sample was mixed well by pipetting up and down until the mixture becomes gluish.  
5. Digested cells were transferred into columns.  
6. Sample was centrifuged for 2 minutes at 13,000rpm at room temperature. Column 
was discarded and tube was closed using rubber lid.  
7. Sample was then stored at -80°C and ready to be delivered to Cambridge for 



































3.1 Antibody Optimization  
 
Immunofluorescence reagents are titrated to ensure proper quality control, to minimize 
wastage of reagents and to reduce lot-to-lot variation. Comparisons should also be made 
between lots when new batch of antibodies are purchased.  The same volume of reagent 
should be used at each dilution point.  
 
Antibodies have a range in which they bind to antigens. If too little antibody is used in the 
labeling, there will be an inaccurate amount of light produced by fluorescence and depending 
on the magnitude, a particle positive for the antibody may not be detected. However using too 
much antibody will increase the background and may mask the true amount of the antigen in 
the sample. Therefore, it is important to find an optimal concentration of fluorescent antibody 
that approached the saturation level, but is slightly below it. This ensures a fluorescent signal 
emission that is linearly proportional to the antigen present in the sample.  
 
0.5 million PBMCs of healthy donors were used to perform each extracellular monoclonal 
antibody titration, meanwhile 1 million PBMCs of healthy donor were aliquoted for each 
intracellular monoclonal antibody optimization. To titrate the antibodies, a starting volume is 
determined, which is typically 1ul, followed by 3ul, 5ul and 10ul. Cells were stained and 
analyzed on flow cytometer on the same day. Positive and negative populations were gated 
on the histograms. The concentration with the best separation between positive and negative 
populations, with the least background noise interference was chosen as the optimal 
concentration.  
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For T Lymphocytes specific antibodies optimization, as shown in Figure 3.1.1, separation of 
negative and positive populations was obvious in (a), (b), (c) and (e). Negative peaks only 
were observed in (d), (f) and (h). Meanwhile (g) displayed positive peaks of different 
titrations. Titrations reached a plateau at 3ul for (a), (b), (c) and (d). 1ul was too low a 
titration concentration for them. Meanwhile 5ul and 10ul gave the same optimal results as 3ul. 
Titration 10ul of chosen for (e), (f), (g) and (h) as they gave the optimal separation compared 
to others, with the least background interference.  
 
Figure 3.1.2 shows the optimization of monocytes and granulocytes specific antibodies, 
CD16-PB (a) titration was optimal at 3ul and 5ul as 10ul gave a high background noise. 3ul 
titration was sufficient to give optimal results. CD14-PE(b) and CD13-APC (c) titration were 
optimal at 10ul. Its histograms shifted to the right whenever a higher concentration was used.  
APC isotype and FITC isotype gave optimal titration at both 5ul and 10ul. 5ul was chosen to 
reduce reagent cost.  
 
For plasma B and memory B cells specific antibodies titration in Figure 3.1.3, 3ul was 
sufficient to generate optimal results for CD19-PE (a) and CD138-FITC (d).  Titrations 
leveled off the rising curve at 5ul for CD38-APC (b) and at 10ul for CD27-APC (c).   
 
As shown in Figure 3.1.4 intracellular antibody titrations, a greater volume of antibodies was 
required to reach optimal optimizations for Bcl2-PE (a), FoxP3 (b) and A647 isotype (c). 
Titrations were at plateau for 10ul for all three antibodies.  
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1 million cells) 
T Lymphocytes  CD3-PC7 6 
 CD8- PB  6 
 CD62L- FITC  6 
 CD25-PE 6 
 IL7R-PE 20 
 CXCR5-PE 20 
 CD45RA-PerCpCy5.5 20 
 PE isotype  20 
   
Monocytes/  CD16-PB  6 
Granulocytes CD14-PE  20 
 CD13- APC 20 
 APC isotype  10 
 FITC isotype 10 
   
B plasma/ CD19-PE 6 
B memory  CD38-APC 10 
 CD27-APC 20 
 CD138-FITC 6 
   
Intracellular T Bcl2-PE 20 
lymphocytes Foxp3 A647 20 
 A647 isotype 20 
 




                      
                       
                      
                     
 
Figure 3.1.1 Antibody optimization for T lymphocyte specific antibodies. This was 
performed by using titration of 1ul (grey), 3ul (green), 5ul (blue) and 10ul (red) for each 
antibody in 0.5million PBMCs of healthy donor: CD3-PC7 (a), CD8-PB(b), CD62L-FITC (c), 
CD25-PE (d), IL7R-PE (e), CXCR5-PE (f), CD45RA PerCpCy5.5 (g) and PE isotype (h). 
Results are representative of three different healthy donors. CD45RA-PerCpCy5.5 was highly 
concentration dependent, as was PE isotype and CXCR5-PE. No significant difference of 
concentration was observed for CD3-PC7, CD8-PB, CD62L-FITC, CD25-PE and IL7R-PE. 




























































































PE isotype CD45RA PerCpCy5.5 
CXCR5 PE IL7R PE 
CD25 PE CD62L FITC 
CD8 PB 
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Figure 3.1.2 Monocytes and granulocytes specific antibodies optimization. Experiment 
was performed by using titration of 1ul (grey), 3ul (green), 5ul (blue) and 10ul (red) for each 
antibody in 0.5million PBMCs of healthy donor: CD16-PB (a), CD14-PE(b), CD13-APC(c), 
APC isotype (d) and FITC isotype (e). Experiment was repeated on three different healthy 
donors. APC isotpe, CD14-PE and CD13 APC were concentration dependent. No significant 












































































                  
 
 
                  
 
Figure 3.1.3 Antibody optimization for plasma B cells and memory B cells specific 
antibodies. Experiment was performed by using titration of 1ul (grey), 3ul (green), 5ul (blue) 
and 10ul (red) for each antibody in 0.5million PBMCs of healthy donor: CD19-PE (a), CD38-
APC (b), CD27-APC(c) and CD138-FITC (d). No significant difference of concentration was 




























































C D19 PE CD38 APC 
CD27 APC  CD138 FITC 
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Figure 3.1.4 Intracellular antibodies titration specific to Bcl2 and T regulatory cells. 
Titration was performed by using titration of 1ul (grey), 3ul (green), 5ul (blue) and 10ul (red) 
for each antibody in 1 million PBMCs of healthy donor: Bcl2 PE (a), Foxp3-A647 (b) and 
A647 isotype (c). Bcl2-PE and Foxp3-A647 are concentration dependent but no significant 

















































A647 isotype  
Foxp3 A647  Bcl2 PE  
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3.2 SGH Patients’ Clinical Information  
 
A total of 25 subjects with confirmed transcriptional profiling (performed in Cambridge) 
were analyzed. However the UK and Singapore cohorts were not studied at the same time and 
were not designed for direct comparison. Nonetheless there were interesting differences in 
the two cohorts.  
 
Of the 25 subjects, 19 of them were SLE patients and 6 were healthy donors. 16 of these 
patients were from SGH while 3 were from NUH. Results of patients’ clinical data were all 
from SGH. With informed consent, 50ml of blood were collected from the patients by the 
research nurse. However, some patients were too weak to give sufficient blood for flow 
analysis.  
 
75% of these SLE patients from SGH were Chinese, 19% were Malay and only 6% were 
Indian. As expected, 87.5% of the SLE patients from SGH who are involved in this study are 
female and overall 86% of these female patients are Chinese. Most of the patients from SGH 
have disease duration of more than five years and they are in remission. Some were on 
immunosuppressive drugs, particularly Prednisolone on the date of blood collection.  
These patients from SGH are 100% ANA positive and 75% showed symptoms of arthritis 




3.2.1 Prognostic Subgroup Classification  
 
Referring to the microarray results (Figure 1.5), 12 of the subjects (9 SLE patients and 3 
healthy controls) are categorized as prognostic subgroup v8.1. Meanwhile 13 (10 SLE 
patients from SGH and 3 healthy controls) were in prognostic subgroup v8.2 (Table 3.2.1). 
This shows that unlike the UK cohort who are mostly CD8.2, the Asian cohort in Singapore 
displays an equal distribution of these two categories.  
 
16 of patients’ blood were collected from SGH meanwhile 3 were from NUH. Most of the 
patients from SGH were in remission and their conditions stabilized with drug therapy. NUH 
SLE patients were usually at flare and were recently diagnosed SLE on date the blood was 
taken. Unfortunately collection of NUH subjects’ clinical information was not as complete as 
SGH. The patients’ clinical characteristics shown below are those from SGH (Table 3.2.1, 
Table 3.2.2, Table 3.2.3, Table 3.2.4, Figure 3.2.1, Table 3.2.5, Table 3.2.6, Table 3.2.7, 




















Table 3.2.1 Confirmed transcriptional profiling of subjects involved in the study. A total 
of 25 subjects were involved in this study. Table shows clinical information and confirmed 
transcriptional profiling for healthy control subjects and patients with Systemic Lupus 
Erythematosus (SLE). Patients display a homogeneous distribution of v8.1 and v8.2 
categories. 16 patients were from Singapore General Hospital (SGH) except three of them 











Profile  Subjects  Details  
v8.1  Patients   = 9  6 from SGH, 3 from NUH  
 Controls  = 3   
           Total v8.1 = 12   
v8.2  Patients  = 10  10 from SGH  
 Controls  = 3   
           Total v8.2 = 13   
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3.2.2 Characteristics of Patients 
75% of these patients from SGH are Chinese, followed by Malay (19%) and Indian (6%), as 
shown in Table 3.2.2. 87.5% of them are female; this shows that SLE clearly has a female 
preponderance. As most of the SLE patients from SGH were diagnosed with the disease years 
ago and mostly are in remission, they tend to be older than the expected child-bearing years 














Table 3.2.2 Clinical characteristics of patients from SGH. Ethnic group, gender and age 
group (on date of blood taken) distribution profile of the SLE patients from SGH. Chinese 
females in age group 21-60 are the majority (75%) of the patients involved in this study, 
followed by Malay (19%) and Indian (6%).  
  
  Female (n=14) Male (n=2) 
Chinese (n=12) 
(75%) 10 2 
<= 20 0 0 
21-40 5 1 
41-60 5 1 
>=60 0 0 
Malay (n=3) (19%) 3 0 
<= 20 1 0 
21-40 1 0 
41-60 1 0 
>=60 0 0 
Indian (n=1) (6%) 1 0 
<= 20 0 0 
21-40 0 0 
41-60 1 0 




 v8.1 (n=6) v8.2 (n=10) 
Female:Male 5:1 9:1 
Malay:Chinese:Indian 1:4:1 2:8:0 
20s:30s:40s:50s 0:3:1:2 1:2:7:0 
Disease Duration 
<5: 5-10: 10-20: 20-30 
0:1:4:1                2:4:2:2 
 
Table 3.2.3 Clinical information of patients from SGH involved in this study. Gender, 
race, age group and disease duration of SLE patients from SGH. In both prognostic 








3.2.3 BILAG Scores of Patients 
 
The patients generally had mild lupus and low lupus activity and this explains why 56% of 
them were assessed with a BILAG Score C, 19% scored D, 12.5% scored B and E 
respectively (Table 3.2.4). Patients who scored BILAG Score C had insignificant changes in 
their lupus activity over time, no indication of new symptoms or a change in immuno-
suppression was detected. Their conditions were generally stable for which symptomatic 
therapy would be sufficient. Comparison between prognostic subgroup v8.1 and v8.2 shows 
that patients who fall in subgroup v8.1 display a relatively higher lupus activity with higher 




BILAG Scores No (n=16) % 
A 0 0.0 
B 2 12.5 
C 9 56.3 
D 3 18.8 
E 2 12.5 
 
Table 3.2.4 BILAG scores of SLE patients from SGH involved in this study. The BILAG 
is a validated tool for assessing lupus activity and comprises clinical as well as laboratory 
parameters. It is thought to be more sensitive change compared to other tools such as SLAM 
(Systemic Lupus Activity Measurement) and SLEDAI (SLE Disease Activity Index). 56% of 
these SLE patients display a BILAG Score C, followed by 19% of D and equal distribution 









                             
Bilag Score of F/M SGH Patients




















Figure3.2.1 BILAG score of SLE patients from SGH, with respective prognostic group 
and gender distribution. Three red filled dots represent active SLE patients from NUH who 
were on flare on date of blood collection. Prognostic group v8.1 generally has a higher 
BILAG Score (higher lupus activity) compared to prognostic group v8.2. Both subgroups are 

















3.2.4 ACR Criteria of Patients 
75% of SGH SLE patients had arthritis and hematologic disorder respectively. Half of them 
developed malar rash and 44% of them developed renal disorder. Patients from prognostic 
subgroup v8.1 seemed to display more prominent symptoms of malar rash (83%), 
hematologic disorder (83%), arthritis (67%) and renal disorder (67%). All the three patients 
who had serositis were also from subgroup v8.1 (Table 3.2.5). All the SLE patients involved 
in this study were tested Antinuclear Antibody (ANA) positive and had elevated levels of 
ANA (>1:20 titration). Almost all of them, 94% were Anti-dsDNA positive and all had 
higher than normal range of Anti-dsDNA readings (> 1:10 titration). The same patients from 
subgroup v8.2 were both ACA (anti-cardiolipin) IgM and ACA IgG positive (Table 3.2.6).  
 
ACR Criteria v8.1 (n=6) v8.2 (n=10) Total (n=16) % 
Malar Rash 5 3 8 50.0 
Discoid Rash 0 3 3 18.8 
Photosensitivity  2 3 5 31.3 
Oral Ulcers 3 2 5 31.3 
Arthritis 4 8 12 75.0 
Serositis 3 0 3 18.8 
Renal Disorder 4 3 7 43.8 
Neurological Disorder 0 1 1 6.3 
Hematologic Disorder 5 7 12 75.0 
Antinuclear Antibody 6 10 16 100.0 
 
Table 3.2.5 ACR criteria of SLE patients from SGH involved in this study. All the SLE 
patients were tested antinuclear antibody positive. 75% of them show symptoms of 
hematologic disorder and arthritis. Half of them developed malar rash, 7 of them developed 
renal disorder, 31% of them are photosensitive and have oral ulcers respectively. Discoid rash, 




3.2.5 Autoantibodies Found in Patients 
 
Autoantibodies v8.1(n=6) v8.2(n=10) Total (n=16) % 
*ANA 6 10 16 100.0 
*Anti-dsDNA 5 10 15 93.8 
Anti-Ro 1 1 2 12.5 
Anti-La 0 1 1 6.3 
Anti-Sm 0 0 0 0.0 
Anti-RNP 1 2 3 18.8 
Anti-Scl-70 0 1 1 6.3 
Anti-Jo 1 0 0 0 0.0 
ACA IgM 0 2 2 12.5 
ACA IgG 0 2 2 12.5 
Lupus Anticoagulant 1 1 2 12.5 
 
Table 3.2.6 shows autoantibodies found in SLE patients from SGH. All the patients are 
ANA positive, followed by 93.8% Anti-dsDNA positive, Anti-RNP positive, 12.5% for Anti-
Ro, ACA IgM, ACA IgG and Lupus Anticoagulant positive respectively. 6.3% of them are 
Anti-La and Anti-Scl-70 positive respectively. None of them is Anti-Sm and Anti-Jo 1 
positive.  
 
*ANA levels higher than 1:20 titration 













3.2.6 Classification of Renal Biopsy in Patients 
 
69% of the patients were not renal biopsy-classified (Table 3.2.7). Of those who were 
classified, one fell under Class III, 2 were categorized Class IV, one had global sclerosis and 
minor abnormalities respectively. Those classified were all from subgroup v8.2 except one 
who was from subgroup v8.1 and was classified Class IV.  
 
 
Renal Biopsy Class No (n=16) % Subgroup 
no classification 11 68.8 NA 
Class II & III 1 6.3 v8.2 
Class IV 2 12.5 both v8.1 
Focal global sclerosis 1 6.3 v8.2 
Minor abnormalities 1 6.3 v8.2 
 
Table 3.2.7 Renal Biopsy classification of SLE patients from SGH involved in this study. 
68.8% of the patients were unclassified, 2 (12.5%) of them were Class IV, one (6.3%) of 














3.2.7 Medications Taken on Date of Blood Collection 
 
Some of these patients were under  treatment on date the blood was taken (Table 3.2.8). 56% 
of them were on Prednisolone, 50% were on Hydroxycholoquine, 19% on Azathiopine and 
MMF respectively. Patients who were on Hydroxycholoquine were mostly from subgroup 
v8.2 (88%).  
 
  v8.1 (n=6) v8.2 (n=10) Total (n=16) % 
Prednisolone 4 5 9 56.3 
Azathiopine 2 1 3 18.8 
Cyclophosphamide 0 0 0 0.0 
Hydroxycholoquine 1 7 8 50.0 
Methotrexate 0 0 0 0.0 
MMF 2 1 3 18.8 
Rituximab 0 0 0 0.0 
 
Table 3.2.8 Medications taken of SGH SLE patients on date of blood taken. 56% of them 














3.2.8 Blood Test Results of Patients  
 
High level of mean reading of Creatinine (Cr) was detected in patients in subgroup v8.1, as 
shown in Table3.2.9. Among these five patients tested, three were in the normal range (48, 
52 and 82 µmol/ litre) with only one outlier scoring an extraordinary high level of Cr, 245 
µmol/ litre, which increases the mean reading enormously. This suggests that the high mean 
reading of the Cr of prognostic subgroup v8.1 is not a genuine figure. Erythrocyte 
Sedimentation Rate (ESR) readings were generally high for both subgroups. White Blood 
Cells (WBC), Neutrophils, Lymphocytes, Complement Component 3 (C3) and Complement 
Component 4 (C4) of these patients were in normal range.  
 
 Mean  v8.1 (total n=6) v8.2 (total n=10) Normal Range 
Cr (µmol/ l) 107.6 (n=5) 70.8 (n=8) 53-106 µmol/ l 
CRP (mg/l) NA (n=0) 6.9 (n=1) 0-1.0 mg/dl 
ESR (mm/h) 71 (n=2) 23 (n=7) 0-15 mm/ hr 
WBC (x10
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/l) 1.6 (n=6) 1.53 (n=10) 0.9-2.9 x 10
9
/ l 
C3 (mg/l) 870 (n=1) 1007 (n=3) 640-1660 mg/ l 
C4 (mg/l) 320 (n=1) 180 (n=3) 150-450 mg/ l 
 
Table 3.2.9 Blood tests done around date of blood collection of SLE patients from SGH. 
Results in red indicate the abnormal range of readings. All the WBC, Neutrophils and 










The age of these female patients tended to be older than the expected child-bearing years as 
they were diagnosed with SLE earlier and had disease duration of more than 5 years. In light 
of this, most patients had mild lupus and this explains the low BILAG Score of mostly C, D 
and E. Immunosuppressive drug therapy also plays a role in the low lupus activity which 
causes them to have very minimal or undetected changes in their lupus activity. Nevertheless, 
patients in subgroup v8.1 displayed a relatively higher BILAG Scores suggesting a higher 
lupus activity than prognostic subgroup v8.2. 
 
Comparing to SGH SLE patients in subgroup v8.2, prognostic subgroup v8.1 seemed to 
develop obvious symptoms like malar rash (83%), hematologic disorder (83%), arthritis 
(67%) and renal disorder (67%). All the three patients who had serositis were also from 
subgroup v8.1. This supports the view that Singapore SLE patients of prognostic subgroup 
v8.1 have more serious manifestations.  
 
All the patients from SGH involved in this study were found to have elevated ANA and Anti-
dsDNA readings. However, a negative ANA test alone does not rule out SLE, but alternative 
diagnoses should be considered. Patterns of staining of ANA may give some clues to 
diagnoses but these patterns may change with serum dilution. Only the rim (peripheral) 
pattern is highly specific for SLE. ANA test should be used only when there is clinical 
evidence of a connective tissue disease. In this case, Anti-dsDNA is a more specific (95% 
specificity) test than ANA as it is more specifically targeted by IgG and IgM antibodies 
directed against host double-stranded DNA, rather than measuring heterogeneous antinuclear 
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antibodies in patient’s serum in ANA diagnosis. Titers of Anti-dsDNA correlate well with 
disease activity and with occurrence of glomerulonephritis and Anti-dsDNA is not found in 
drug-induced SLE. 
 
88% of SLE patients from SGH who were on Hydroxycholoquine on day of blood collection 
were from subgroup v8.2. Does this suggest that Hydroxycholoquine reduces the 
manifestations of the disease? This needs to be confirmed with a large patient population. 
The possibility of subgroup switching also needs to be monitored. Anegret and colleagues 
described that corticosteroids and cyclophosphamide could significantly restore the decreased 
number of T reg cells (Kuhn, et al 2009). But none of the patients involved in this study was 
on these drugs at the time of blood collection. Two other groups found a significant increase 
of CD4+CD25+ Treg in cell proportion following B cell depletion with Rituximab in lupus 
patients (Sfikakis, et al 2007, Vallerskog, et al 2007). But unfortunately there was no SGH 
patient involved who was on Rituximab for us to verify this observation in our study.  
 
ESR readings were generally high for both subgroups, suggesting the possibility of infections 
and inflammatory disease in these SLE patients which causes the aggregations of 
erythrocytes in plasma settle rapidly. However, even though there is a good correlation 
between ESR and Cr, Cr levels in these patients were mostly in the normal range. This is due 
to the incomplete data collection and the mean levels analyzed were performed on different 
patients. WBC and Lymphocytes counts of these SLE patients were safely in the normal 
range, suggesting that current infection and inflammation was involved. The neutrophil count 
was surprisingly in the normal range of 1.8-6.8 x 10
9 
cells/l, despite the fact the high level of 
ANA found in the serum. ANA are produced in SLE or other autoimmune disease and 
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destroy neutrophils and subsequently reduce the number of neutrophils in blood. The 
concentration of C3 and C4 of these patients was also in the normal range and the expected 

























































4.1 T Lymphocyte Analysis 
4.1.1.1 Extracellular Staining Analysis for IL7R, CD25 and CXCR6 
100ul of whole blood was lysed and stained with anti-CD3, CD8, CD45RA and CD62L to 
give four T cell populations: T naïve (Tn), T central memory (Tcm), T effector memory (Tem) 
and T revertant memory (Temra), as shown in Figure 4.1.1.  
 
Proportions of all four CD8 and CD4 T memory subsets, particularly the T memory 
population (Tcm+ Tem) of the Asian cohort were compared with the UK cohort in both 
prognostic subgroups v8.1 and v8.2, with and without the inclusion of healthy controls.  
Samples were also stained to quantify expression of IL7R, CD25 and CXCR6 respectively. 
The objectives of quantifying these markers are elaborated in later sub-chapters. But 
generally the data analysis for T lymphocytes is depicted in Figure 4.1.1, based on a single 
patient’s data. Whole blood cells were lysed and stained with multicolour antibodies. 
CD3+CD4+ and CD3+CD8+ populations were later gated to further analyze memory T 
subsets using CD62L versus CD45RA.   
 
In multicolor flow experiments, it is not possible to set gates based on an entirely unstained 
or fully isotype stained control. A control is defined as changing one variable condition at a 
time. Fluorescence Minus One (FMO) controls leave out one reagent at a time, it acts like the 
opposite of single colour controls.  Thus FMO method was used as gating strategy in the 
analysis of expression quantification, as shown in Figure 4.1.2. Mean Fluorescence Intensity 
(MFI) for each histogram was collected in geometric mean.  
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Figure 4.1.1 FACS data analysis for T lymphocytes. Whole blood cells from a patient were 
lysed and stained with monoclonal antibodies specific for CD3-PC7, CD8-PB, CD45RA-
PerCpCy5.5 and CD62L-FITC, samples were acquired using a Beckman Coulter CyAn. (a) 
Lymphocyte population gated in scatter plot was then applied to (b). CD3+CD8+ and 
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 cells were termed T revertant cells. T memory cells are a 
combination of T central memory and T effector cells. 
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Figure 4.1.2 Gating Strategy for T Lymphocytes Analysis. Lysed whole blood cells were 
stained with monoclonal antibodies specific for CD3-PC7, CD8-PB, CD45RA-PerCpCy5.5, 
CD62L-FITC and PE-conjugates (IL7R or CD25 or CXCR6). Positive gatings were 
established using fluorescence minus one (FMO) isotype controls as shown in the histograms 
for T central memory (a), T naïve (b), T effector memory(c) and T revertant cells (d). Mean 













4.1.1.2 CD8 and CD4 T Memory Subsets  
Comparisons between the UK and Asian SLE cohorts (with and without healthy controls) for 
CD8 and CD4 T memory subsets proportions in prognostic subgroups v8.1/4.1 or v8.2/ v4.2 
were laid out from Figure 4.1.3 to 4.1.6. Red dots represents the active SLE patients from 
NUH.  
 
Compared to the UK SLE cohort, the Asian cohort displays a different trend of CD8 T 
memory cells. The Singapore SLE cohort had almost double the proportion of naïve CD8 T 
cells in both prognostic subgroups, 40% in Asian 20% in UK cohort (Figure 4.1.3 (a) & (c)). 
Patients in subgroup v8.1 had one third less CD8 T memory cells (a combination of CD8 T 
central memory, CD45RA-CD62L+ and CD8 T effective memory CD45RA- CD62L- cells). 
However, both UK and Singapore SLE cohort had a similar range of CD8 Temra 
(CD45RA+CD62L-) cells. Inclusion of healthy controls did not change the profile of 
Singapore SLE cohort significantly (Figure 4.1.3 (b)).  
 
Comparisons between v8.1 and v8.2 in T memory population (T central memory and T 
effector memory cells) are highlighted in Figure 4.1.4. It is reported that subgroup v8.1 has a 
higher CD8 T memory population compared to subgroup v8.2 in the UK cohort (Figure 4.1.4 
(c)). However this does not occur in Singapore cohort with (Figure 4.1.4 (b)) and without 
(Figure 4.1.4 (a)) the inclusion of healthy donors. The Singapore cohort had a homogenous 
distribution of CD8 T memory cells in both prognostic subgroups.  
 
Referring to Figure 4.1.5, the proportion of CD4 T memory subsets was very much similar to 
the UK CD8 T memory subsets profile, regardless the inclusion of healthy controls’ data, as 
92 
shown in Figure 4.1.5. There were generally more CD4 T memory cells and a smaller CD4 T 
naïve cell proportion in subgroup v4.1 than v4.2. Similar to the UK cohort, a higher CD4 T 
memory population in subgroup v4.1 is clearly seen in Figure 4.1.6 (a) & (b) and this is 
statistically significant. This shows the possibility of CD4 being a better gene signature for 



















                                              


































                                          


































                                                
 
Figure 4.1.3 Comparison of CD8 T memory subsets in Asian and UK cohort. Proportions 
of CD8 T memory subsets of Asian cohort in prognostic group v8.1 and v8.2, without (a) and with (b) 
the inclusion of data of healthy controls, as compared to UK cohort (c). The Asian cohort displays a 
different trend of CD8 T memory cell subset proportions compared to the UK cohort. The Asian 
cohort has double the proportion of T naive cells: 40% in Asian (a): 20% in UK cohort(c). The Asian 
also displayed a lower T memory populations (T central memory + T effector memory cells) in 
prognostic group v8.1. Both UK and Asian cohorts display a similar trend of CD8 T memory subsets 
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Figure 4.1.4 CD8 T memory (Tcm +Tem) comparison between Asian and UK cohort. 
Asian cohort v8.1 has a slightly higher CD8 T memory cells (Tcm +Tem) percentage 
compared to v8.2 (a)(b), similar to the trend shown in the published data by Cambridge (c). 
But they are not statistically significant.  
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Figure 4.1.5 Comparison of CD4 T memory subsets in Asian and UK cohort. Proportions 
of CD4 T memory subsets of Asian cohort in prognostic group v4.1 and v4.2, without (a) and with (b) 
the inclusion of data of healthy controls, as compared to CD8 T memory subsets of UK cohort (c). 
Asian cohort displays a similar trend of CD4 T memory cell subset proportions compared to the UK 
cohort.  
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Figure 4.1.6 CD4 T memory (Tcm +Tem) comparison between Asian and UK cohort. 
Like the UK cohort, the Asian cohort v4.1 has a slightly higher CD4 T memory cells (Tcm 
+Tem) percentage compared to v4.2 (a)(b), similar to the trend shown in the published data 
by Cambridge (c). They are statistically significant.    
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4.1.1.3 Quantification of IL7R Expression  
 
Memory T cell precursors are present at the peak of the immune response. But memory T 
cells do not display their function, such as survival, which are progressively acquired with 
transcriptional signatures as the antigen is cleared (Kaech, et al 2002). Effector T cells which 
do not persist long-term in the absence of antigen, are unable to undergo homeostatic 
proliferation as they fail to acquire key properties of memory cells like IL7R at early time 
points.  
 
The survival of memory T cells is dependent on the expression of anti-apoptotic molecules 
like Bcl2 (Rathmell and Thompson 2002) and the cells’ capacity to respond to homeostatic 
cytokines like IL-7 which enhances survival (Li, et al 2003). IL7R expression identified the 
memory precursors at early time points. IL7R hi cells were found to contain high amounts of 
anti-apoptotic molecules and conferred protective immunity (Huster, et al 2004, Kaech, et al 
2003).  
 
As displayed in Figure 4.1.7, no significant difference between the expression levels 
(measured by Mean Fluorescence Intensity, MFI) was detected between subgroups v8.1/ 4.1 
and v8.2/ 4.2 in both CD8 and CD4 T subsets. However, CD4 T memory and CD4 T naïve 
subsets shows a higher cell proportions expressing IL7R+ in v4.1 than in v4.2 (Figure 4.1.8 
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Figure 4.1.7 Expression of IL7R in CD4 and CD8 T Memory subsets, between v8.1 and v8.2.  
Geometric Mean fluorescence intensity (MFI) of cells expressing IL7R+ in CD8 (a, c) and CD4 T 
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(b)(a)
Figure 4.1.8 Cell proportions of IL7R+ CD4 and CD8 T Memory subsets, between v8.1 and 
v8.2.  Proportions of cells expressing IL7R+ in CD8 (a, c) and CD4 T (b, d) memory subsets, 
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4.1.1.4 Quantification of CD25 Expression  
 
Quantification of CD25 (also termed as IL2R), is an indicator of T lymphocyte activation that 
can be used to track disease activity and progression (Smith 1988, Smith 1990). CD25 is the 
alpha chain of the IL-2 receptor. It is a type I transmembrane protein present on activated T 
cells and B cells, on macrophages, and on a subset of non-activated CD4
+
 regulatory T cells. 
These membrane-bound molecules CD25 (55-65kDa in size) are expressed and released in 
soluble form, sIL2R (a truncated form of its receptor, 45-55kDa in size) by activation of T 
lymphocytes (Nelson, et al 1986, Rubin, et al 1986). The rate of release of soluble CD25 
correlates to its cell surface expression and thus to the level of activation of the T 
lymphocytes (Rubin, et al 1986, Symons, et al 1988). Serum levels of soluble CD25 are 
claimed to be proportional to the disease activity in patients with SLE (Spronk, et al 1994, ter 
Borg, et al 1990). 
 
Both CD8 and CD4 T subsets (except CD8 Temra) of subgroup v8.2/ 4.2 exhibited elevated 
expression of CD25 (Figure 4.1.9). But this data was not statistically significant. On the 
contrary, prognostic subgroup v8.1/ 4.1 generally gives a slightly higher cell percentage in 
both CD8 and CD4 T subsets, as shown in Figure 4.1.10. 
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Figure 4.1.9 Expression of CD25 in CD4 and CD8 T Memory subsets, between v8.1 and 
v8.2.Mean fluorescence intensity (MFI) of cells expressing CD25+ in CD8 (a, c) and CD4 T 
(b, d) memory subsets, with (a, b) and without (c, d) the inclusion of healthy controls.  
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Figure 4.1.10 Cell proportions of CD25+ CD4 and CD8 T Memory subsets, between v8.1 and 
v8.2.Proportions of cells expressing CD25+ in CD8 (a, c) and CD4 T (b, d) memory subsets, with 
(a, b) and without (c, d) the inclusion of healthy controls.  
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4.1.1.5 Quantification of CXCR6 Expression  
 
CXCR6 is a unique receptor for CXCL16, a chemokine expressed on the cell surface as 
membrane-bound molecules (Shimaoka, et al 2004). Based on conserved cysteine motifs, 
chemokines which induce leukocyte migration are generally classified as C, CC, CXC, CX3C 
chemokines (Yoshie, et al 2001). It has been shown that CXCR6 is expressed on the 
peripheral blood T cells of Th1 phenotype, NK cells and B cells (Kim, et al 2001). Toshihiro 
and colleagues described that CXCL16 play an important role in T cell migration and that it 
was stimulated in the synovium of patients with RA (Nanki, et al 2005). They also found that 
CXCR6 was expressed more frequently on synovial T cells of RA patients rather than in 
peripheral blood and stimulation of these cells with IL-15 will increase expression of CXCR6. 
Sato and colleagues observed that CXCR6 was required for lymphocyte proliferation or 
amplification of the inflammatory reaction. CXCR6 also facilitates effector CD8 T cell 
localization from blood into sites of pathological inflammation and thus contributes to the 
recruitment of activated lymphocytes into an inflamed liver (Sato, et al 2005).  
 
There was generally no significant difference shown in CXCR6 expressions in both 
subgroups in both the CD8 and CD4 T subsets. However, expression of CXCR6 appeared 
higher in CD4 T naïve of subgroup v4.2; regardless the inclusion of healthy controls (Figure 
4.1.11). But the data was not statistically significant. The CD4 T naïve cell proportion 
expressing CXCR6+  also appeared to be higher in subgroup v4.2 than subgroup v4.1. 
Generally across the cell proportion expressing CXCR6+ data, subgroup v8.2/4.2 appeared to 
be a higher proportion of T subsets (Figure 4.1.12). 
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(c) (d)
Figure 4.1.11 Expression of CXCR6 in CD4 and CD8 T Memory subsets, between v8.1 and 
v8.2.Mean fluorescence intensity (MFI) of cells expressing CXCR6+ in CD8 (a, c) and CD4 T (b, 
d) memory subsets, with (a, b) and without (c, d) the inclusion of healthy controls.  
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Figure 4.1.12 Cell proportions of CXCR6+ CD4 and CD8 T Memory subsets, between v8.1 
and v8.2.Proportions of cells expressing CXCR6+ in CD8 (a, c) and CD4 T (b, d) memory subsets, 
with (a, b) and without (c, d) the inclusion of healthy controls.  
 
106 
 4.1.2 Intracellular Bcl2 Analysis 
 
Bcl2 is expressed in a variety of hematopoietic lineages including T cells, it is a proto 
oncogene which was identified due to its involvement in non-Hodgkin B cell lymphoma. A 
t(14:18) interchromosomal translocation juxtaposes the Bcl2 gene which consequently leads 
to transcription of high levels of Bcl2 (Graninger, et al 1987) and eventually enhances cell 
survival. The intracellular protein is found on the mitochondrial membrane (Hockenbery, et 
al 1990), perinuclear membrane and endoplasmic reticulum (Alnemri, et al 1992, Jacobson, 
et al 1993). Bcl2 appears to enhance lymphoid cell survival by interferring with apoptosis 
rather than promoting cell propagation (Rose, et al 1994).  
 
Ohsako described that expression of Bcl2 in T lymphocytes from SLE patients was 
significantly higher, compared to inactive SLE patients and healthy individuals (Ohsako, et al 
1994). In autoimmune mice, the abnormal expression of a number of genes, including Bcl-2 
gene influence apoptosis have been identified (Veis, et al 1993). The aberrant expression of 
these genes (also called autogenes) is believed to result in defective apoptosis (Talal 1994) 
(Mountz, et al 1994) and development of maglinancy. Studies have shown that SLE might be 
due to the failure of immune system to eliminate autoreactive immune cells, which leads to 
the abnormal longetivity of these cells and elevated autoantibody production (Ohsako, et al 
1994, Rose, et al 1994). 
 
The profile pattern of Bcl2 expression in the Singapore cohort CD8 T memory subsets 
(Figure 4.1.14(a) & (d)) is very much similar to the UK cohort (Figure 4.1.14(c)), but with 
significant higher fluorescence intensity of Bcl2 expression. Two possibilities to explain the 
phenomenon are:  
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- The Asian cohort seems to have one-fold more intense or defective anti-apoptotic Bcl2 
expression in T lymphocytes compared to the UK cohort, judging that the MFI readings of 
Bcl2 expression is twice as high as the UK cohort.  
- This does not represent increased Bcl2 expression and could it be simply due to the different 
signal-to-noise ratio of instruments used in Singapore Immunology Programme and 
Cambridge Institute of Medical research. This needs to be further clarified by repeating the 
same sample in both institutes with the same batch of antibodies used, same brand and model 
of instrument used.  
 
All CD4 and CD8 T memory subsets display higher cell proportions expressing Bcl2+ in 
subgroup v8.1/4.1 and they are statistically significant, as shown in Figure 4.1.15. This 














              
      











Figure 4.1.13 Example of flow data analysis of ficolled PBMC from a SLE patient for Bcl2 
intracellular staining. Lymphocytes were gated in the scatter plot (a) and then applied to CD3 
PC7- CD8 PB dot plot (b). CD3+CD8+ population was gated and applied to CD45RA 
PerCpCy5.5- CD62L FITC dot plot on (c). CD3+CD8- region was applied to CD45RA 
PerCpCy5.5- CD62L FITC dotplot on (d). Four distinguished T cell memory subsets can be 
found both dot plots (c) and (d).  
CD3 PC7 
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Figure 4.1.14 Example of Bcl2-PE expression analysis in T memory subsets of CD8 
Tcells. Fluorescence Minus One (FMO) with Bcl2 isotype served as a baseline to measure 
Bcl expression in T naive cells, T central memory cells, T effector memory cells and T 
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Figure 4.1.15 Expression of Bcl2 in CD4 and CD8 T Memory subsets, between v8.1 and 
v8.2.Geometric Mean fluorescence intensity (MFI, Geometric Mean) of cells expressing Bcl2+ in 
CD8 (a, d) and CD4 T (b, e) memory subsets, with (d, e) and without (a, b) the inclusion of healthy 
controls, as compared to UK cohort (c), courtesy by E.F McKinney, P A Lyons et al Nature Medicine 
2010 
UK Cohort SLE Patients 
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Figure 4.1.16 Cell proportions of Bcl2+ CD4 and CD8 T Memory subsets, between v8.1 and 
v8.2.Proportions of cells expressing Bcl2+ in CD8 (a, c) and CD4 T (b, d) memory subsets, with (c, 




4.2 Monocyte and Granulocyte Analysis 
 
Differential expression of CD14 and CD16 (also known as FcγRIII) allow human blood 
monocytes to be divided into two major subpopulations: CD14++CD16- and CD14+CD16+ 
monocytes (Gordon and Taylor 2005). CD14++CD16- are often called classic monocytes as 
the phenotype resembles the original description of monocytes. It was shown that 
CD14+CD16+ monocytes expressed higher amounts of MHC class II molecules and CD32 
(also known as FcγRII) (Ziegler-Heitbrock 1996). It was suggested that these cells resemble 
mature tissue macrophages (Ziegler-Heitbrock, et al 1993)(Ancuta, et al 2000).  
 
CD14+CD16+ monocytes are smaller (an average size of 13.8µm) and less granular than 
regular monocytes (18.4µm in size). They account for 2.2% of the mononuclear cells 
(Passlick, et al 1989) These non-classical monocytes are potent producers of TNFα (Ancuta, 
et al 2000, Belge, et al 2002) but produce very low IL-10, suggesting that they are 
proinflammatory cells. They also show a higher antigen-presenting capacity. It appears that 
CD14+CD16+ monocytes play a critical role in infection and inflammation (Ziegler-
Heitbrock 2007), they were found to be significantly increased in Rheumatoid Arthritis 
patients (Kawanaka, et al 2002).  
 
A higher CD14+CD16lo monocyte percentage was found in v8.1 but the difference is not 
significant, as shown in Figure 4.2.3(a).There is no significant difference of CD14+CD16+, 
CD14-CD16++, CD14-CD16+ and Eosinophils cell proportions between subgroups v8.1 and 
v8.2, as shown in Figure 4.2.3(b). Unlike active lupus patients, most of the Singapore 
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patients involved in this study are quiescent and in remission, thus less inflammation and 
infection as exhibited by these patients. TNFα should be included in future research 
experiments to serve as a potential biomarker for prognostic subgroups v8.1 and v8.2.  
 
Figure 4.2.4(a) shows that CD16loCD14+ of subgroup v8.1 displays a higher cell proportion 
expressing CD13+. Eosinophils in subgroup v8.2 show a slightly higher cell percentage 
expressing CD13+ than subgroup v8.1. All the subsets of v8.1 display higher cell proportions 








               
 
























(a)Figure 4.2.1 Flow data analysis of lysed RBC from a SLE patient for monocytes and 
granulocytes analysis. Granulocytes and monocytes were gated in the scatter plot (a) and single 
cells were gated at (b). Five populations were gated on CD14PE- CD16PB dotplot: CD14+CD16+, 
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Figure 4.2.3 CD14+CD16lo cell proportions in v8.1 and v8.2 and cell proportions of different 
subgroups of monocytes and neutrophils. Comparison of CD14+ CD16lo cell proportions between 
prognostic group v8.1 and v8.2 (a). An overview of cell proportions of different subpopulations between 
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Figure 4.2.4 Monocytes and neutrophils cell subsets proportions expressing CD13+ and 
CD62L+. Cell proportions of different populations between prognostic groups v8.1 and v8.2: 
(CD14+CD16+, CD14-CD16++, CD14-CD16+, CD14++CD16lo and Eosinophils) expressing 
CD13+ (a) and CD62L (b). Red filled dots represent NUH patients who were on flare on date of 
blood collection.  
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4.3 Plasma B and Memory B Cell Analysis  
 
SLE is an autoimmune disease where B-cell functions are closely correlated with disease 
activity. Abnormal B cell and T cell recognition of self-antigens leads to the production of 
autoantibody. Autoantibodies produced by B-cell-derived plasma cells also contribute 
significantly to the disease pathogenesis such as immune complex formation, complement 
activation and tissue destruction (Yanaba, et al 2008). The immune complexes formed have a 
central role in the effector phase of the disease (Kotzin 1996).  
 
In vivo, antigen-specific activation and differentiation of B cells occur in germinal centers. 
Within germinal centers, CD19+CD27- naïve B cells undergo activation, proliferation, 
somatic hypermutation, Ig isotype switching and positive/ negative selection by antigen 
(MacLennan, et al 1992, Zhang, et al 2008, Zheng, et al 1997) . Activated B cells mature into 
antibody producing plasma cells (CD19+CD38+) or become memory B cells (CD19+CD27+) 
(Liu and Banchereau 1997). An enlarged pool of memory B cells poses a risk for 
autoimmunity since these cells have lower activation thresholds (Dorner, et al 2009, Sato, et 
al 2004).   
 
Active SLE patients are reported to have a slightly higher proportion of CD19+ B cells and 
increased frequency of CD19+CD27+ peripheral B cells, due to a reduction of CD19+CD27- 
naïve peripheral B cell pool and a lesser decline in CD19+CD27+ memory B cells (Odendahl, 
et al 2000). CD19+CD38+CD138+ mature plasma B cells were found to have higher 
frequencies in active but not inactive SLE patients (Odendahl, et al 2000).  
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My investigation results show that there is no significant difference in CD19+ B cells and cell 
frequencies in Memory B and Plasma B cells between the two prognostic groups, as depicted 
in Figure 4.3.1. 
 
Figure 4.3.2(a) shows no significant difference of cell proportion expressing CD19+ B cells 
in both subgroup v8.1 and v8.2. Proportion of CD27+CD62L+ B cells is higher in subgroup 
v8.1 than in v8.2. Subgroup v8.2 displays a higher cell proportions in both CD27-CD62L+ 




         
              
R2















Figure 4.3.1 An example of flow data analysis of whole blood after RBC lysis for B plasma 
and B memory cells. Lymphocytes were gated in (a) and CD19+ B cells were gated in (b), these 
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Figure 4.3.2 CD19+ cell proportions in v8.1 and v8.2 and cell proportions of different 
subgroups of B memory and B plasma cells (CD38+CD138-). Proportions of CD19+ B cells in 
prognostic group v8.1 and v8.2 (a). Cell proportions of different populations between prognostic 
groups v8.1 and v8.2 : CD27+CD62L+, CD27+CD62L-, CD27-CD62L+, CD38+CD138- (b).  
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4.4 Regulatory T Cell Analysis 
 
Natural T reg cells are characterized by a constitutive expression of CD25 on the surface of 
CD4 T lymphocytes. They show a potent immunosuppressive function and contribute to 
immunologic self-tolerance by suppressing potentially auto-reactive T cells. Deficiency in T 
regulatory function may result in increased helper T cell activity or directly enhanced B cell 
activity. Several studies have been published regarding the phenotype and function of 
CD4+CD25+ T reg in patients with SLE.  However, the literatures were conflicting. As 
compared to healthy controls, most labs found significantly decreased frequencies of 
CD4+CD25++ T reg in SLE patients (Barath, et al 2007a, Barath, et al 2007b, Bonelli, et al 
2008, Crispin, et al 2003, Fathy, et al 2005, Lee, et al 2006, Lyssuk, et al 2007, Mellor-Pita, 
et al 2006, Miyara, et al 2005, Valencia, et al 2007, Vargas-Rojas, et al 2008, Zhang, et al 
2008). In contrast, Sfikakis and colleagues showed that the T regulatory functional marker 
Foxp3 was increased significantly in all patients (n=7) examined, following B cell depletion 
with Rituximab in patients with lupus nephritis (Sfikakis, et al 2007). Vallerskog and 
colleagues also reported that rituximab-induced B cell depletion in SLE patients increased the 
proportion of T reg cells (Vallerskog, et al 2007). However, further studies should be 
performed to determine whether modulations of T reg by therapeutic B cell depletion 
contributes and predicts lupus activity.  
 
The population of CD4+CD25+ in subgroup v8.2 showed a slightly higher expression of 
Foxp3+ than in v8.1 (Figure 4.4.2(a)). However, subgroup v8.1 had a higher cell proportion 
expressing Foxp3+ than subgroup v8.2 (Figure 4.4.2(b)). No significant difference of T reg 
functional Foxp3 expression in the two prognostic subgroups of v8.1 and v8.2 was observed. 
The cell proportion of T reg in v8.1 (~50%) was slightly higher than v8.2 (~40%).  
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Figure 4.4.1 An example of flow data analysis of ficolled PBMCs for regulatory T cells. 
Lymphocytes were gated in (a) and CD4+CD25+ T cells were gated in (b), these two gates were 













































































Figure 4.4.2 Quantification of CD4+CD25+ cells expressing Foxp3 in MFI and cell percentage. 
MFI (Geometric Mean) of Foxp3 A647 in CD4+CD25+ T Lymphocytes between prognostic group 
v8.1 and v8.2 (a). (b) shows the CD4+CD25+ T cell proportions expressing Foxp3 in prognostic 





























5.1 Aims of Study   
 
SLE is an autoimmune disease with manifestations derived from the involvement of multiple 
organs. Recent findings from various studies have improved our understanding of SLE and 
reshaped current models. Even though the survival rate of the SLE patients has increased 
significantly over the years, complications arising from the use of toxic immunosuppressive 
drugs still cause considerable health difficulties.  
 
Here, we review recent findings by our collaborators to identify prognostic subgroups based 
on the mRNA transcriptional profiling in an Asian cohort. As mentioned earlier in Chapter 1: 
Introduction, phenotypic analysis of the CD8 T cells revealed increases in the proportion of 
memory cells, as well as higher expression of BCL-2 and IL7R in the v8.1 group compared to 
v8.2. This study was performed in SLE patients from UK cohort. It was also reported that 
lupus patients in the 8.1 group had a poorer prognosis with a shorter time to first flare and an 
increased flare rate.  
 
We aimed to determine if similar differences to the European population exist in these 
prognostic subgroups (v8.1 and v8.2). In addition, we aimed to study the phenotypes of CD4 
and CD8 T cells in normal and lupus diagnosed in Asian populations. On top of all these, we 
aimed to see if flow cytometry would be a quicker, less painful for patients (for lesser blood 
volume) more efficient and economic tool to substitute microarray to classify SLE patients to 




5.2 Discussion: Main Observations and Findings  
 
The Singapore cohort was observed to have relatively homogeneous proportions of memory 
cells (CD8 Tcm + Tem). The CD8 T naïve populations (~49% respectively) in both 
subgroups v8.1 and v8.2 are relatively similar in proportions, this suggests that, compared to 
the UK cohort, CD8 T memory subsets of the Singapore cohort were less activated with a 
lower cell percentage of CD8 T memory and higher CD8 T naïve. In the UK cohort, the 
proportion of CD8 T memory cells (CD8 Tcm +Tem) in subgroup v8.1 was higher than in 
v8.2. But this is not the case in Singapore. The local cohort has a similar cell percentage 
(40%) in both subgroups. Therefore the pattern of CD8 T memory subsets dot plot profile in 
CD45RA versus CD62L (McKinney, et al 2010) does not serve as a sensible and valid 
biomarker to classify the subgroup in the Singapore population. In comparison to subgroup 
v8.2, patients that fall in prognostic subgroup v8.1 are reported to have more severe SLE 
disease manifestations, shorter time to first flare, more frequent disease flare per month of 
follow-up.  
 
Nonetheless, the trend of CD4 T memory subsets observed was very much similar to the UK 
cohort CD8 T memory subsets profile, and they are statistically significant. CD4 T memory 
(Tcm +Tem) displayed the highest proportions, followed by Naïve T cells and T revertant 
cells showed to be the least subgroup. CD4 T memory cells (CD4 Tcm+Tem) display a 
higher cell proportion in v4.1 T memory as featured in the UK cohort CD8 T memory cells. 
Naïve T cells population has a lower cell proportion in subgroup v4.1 compared to v4.2. This 
suggests that more naïve T cells had been converted to become CD4 T memory cells 
(Tcm+Tem), indicating that these SLE patients in subgroup 4.1 have a more active immune 
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response. This also suggests the possibility that the CD4 T memory proportion serves as a 
better diagnostic biomarker for the Asian cohort.  
The proportion of cells expressing IL7R+ in CD8 T memory subsets are higher in v8.1 than 
v8.2. IL7R is a cardinal feature acquired by memory T cells at early time points to enhance 
their survival. This suggests that CD8 T memory subsets in prognostic group v8.1 are more 
rapid and advanced in acquiring IL7R feature than group v8.2. As identified by Huster, this 
IL7R+ CD8 T memory cells contain higher number of anti-apoptotic molecules and thus 
enhance their survival (Huster, et al 2004).  
 
Contrary to the belief that subgroup v8.1 of CD8 T memory subsets is more aggressive and 
intense than v8.2, CD25 expression appeared to be higher in CD8 and CD4 T memory 
subsets of subgroup v8.2 (data was not statistically significant). However, subgroup v8.1 has 
a higher cell proportion expressing CD25+ in both profiles of CD8 and CD4 T memory 
subsets. This could indicate the possibility of subgroup v8.2 having a higher lupus activity 
but lower cell count.  
 
Generally group v8.2/4.2 appeared to display a higher proportion of cells expressing 
CXCR6+ in all T memory subsets for both CD8 and CD4 T subsets (data not statistically 
significant). Sato and his group observed that CXCR6 was required for lymphocyte 
proliferation or amplification of the inflammatory reaction. It was also reported that CXCR6 
facilitates effector CD8 T cell migration from the blood into sites of pathological 
inflammation and thus contributes to the recruitment of activated lymphocytes into inflamed 
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liver (Sato, et al 2005). My results indicate that group v8.2/4.2 could have more cells 
proliferating and migrating from the blood stream into sites of pathological inflammation.  
The Asian CD8 T subsets display a similar trend of Bcl2 expression in MFI (Geometric Mean) 
compared to UK cohort but with a significantly higher fluorescence intensity. Both CD4 and 
CD8 T memory subsets showed a higher proportion of cells expressing Bcl2+. My findings 
were in line with the observations of Ohsako who believed that higher Bcl2+ expression in 
SLE patients might be due to a defective of the immune system to eradicate autoreactive 
immune cells. This consequently caused the abnormal survival of these immune cells which 



















Figure 5.1 Summarizes the possible biomarkers to classify patients under prognostic 
subgroup of v8.1 in T memory cell analysis compared to subgroup v8.2. Prognostic 
subgroup v8.1/ 4.1 has a higher cell proportion of CD4 Tmemory (Tcm +Tem) in v4.1 and 
higher frequencies of cells expressing IL7R in CD4 T memory (Tcm + Tem). In general, in 
all CD4 and CD8 T memory subsets, subgroup v8.1 presents a higher cell proportions 
expressing Bcl2+, lower cell frequencies expressing CXCR6+ and lower Mean Fluorescence 
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5.3 Limitations of the Study 
 
Of the total 25 subjects participated in the study, 19 were SLE patients. Among them, only 3 
of the SLE patients were from NUH and were at disease flare and with active inflammation 
on the date of blood collection. The rest of the SLE patients involved were from SGH and 
were in remission with a stable condition and an average of more than 10 years of disease. 
Access to active SLE patients is limited as this is usually dependent on the conditions of the 
patients (as assessed by doctors) and most were considered too weak to donate blood for the 
study. Some were not thought fit to donate the volume of blood needed for the study. This 
explains why we do not have sufficient patients to phenotype by flow cytometry. Repeated 
blood donation at different times after first flare seemed almost impossible. These patients 
usually do not return for the blood donation after they recover from the first flare. This 
complicates our intention to monitor the changes in disease development and phenotypic 
expression in patients over time. 
 
 To boost the number of active SLE patients, this study should be extended to other 
neighboring countries like Indonesia, Thailand and Vietnam which do have a high prevalence 
rate of SLE. Furthermore such an SLE study has not been conducted in these countries.  
 
One of the issues we encountered was low RNA yield which was not sufficient for 
microarray profiling in Cambridge. Unlike the UK cohort who donated 100ml of blood, the 
Singapore cohort was only allowed to give 50ml, as limited by the Singapore IRB. Storage 
duration and conditions, delivery conditions from Singapore to Cambridge UK could also 
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affected the stability of RNA. The possibility of sending the RNA to a reliable local 
microarray facility lab would prevent the loss of RNA, save time and reduce cost of 
producing the array.  
 
Instrument background noise (electronic noise) should be verified by running instrumental set 
up calibration beads, such as 8 Peak beads to ensure the separation of signal to background 
noise is significant. Tracking beads are useful in this context to track the performance and 
target brightness of each Photomultiplier tubes, filters and mirrors of each detector. These 
beads should be used concurrently in both labs (Singapore and Cambridge) in order to ensure 
a fair comparison of results generated.  
 
More functional intracellular markers like IFN-γ and TNF-α should be included in this study 
to check the function and status of the memory cells in different prognostic subgroups. 
Current panel is not expansive enough to answer the functional aspects of T memory subsets. 
More markers should be screened based on the gene profiling of microarray to create a panel 
of biomarkers to segregate patients of different levels of disease manifestations.  
 
Communications among doctors, researchers and research nurses could be more effective by 
constantly having meetings and discussions about the findings of the study.  In depth 
trainings need to be more organized and accurate in patient management, blood collection 
and screening as well as in data collection. More awareness and involvement from all parties 
are needed to benefit the patients in long run.  
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In conclusion, the study was underpowered. It is limited by the number of SLE patients, 
especially those with active SLE. Nevertheless, from the results obtained, CD4 seems to be a 
better gene signature for Asians than CD8. This synchronizes with the recent gene profiling 
of an Asian cohort from Cambridge (data yet to be released), where they did find that CD4 is 
a better gene signature to classify the patients into the different prognostic subgroups. This 
shows that flow cytometry can draw similar conclusions to that obtained by microarray and 
suggests that flow cytometry can be used to recognize different prognostic subgroups of 
patients and allow individualized therapy to reduce SLE severe manifestations. However, 
more biomarkers should be identified and included in the panel to empower the credibility of 
the study.  
 
 
5.4 Future Work  
Telomeres are the repeating hexameric sequence of nucleotides (TTAGGG) found at the ends 
of linear chromosomes (Blackburn 2001, Hodes, et al 2002). Each division of a cell leads to 
the loss of 50-100 base pairs of telomeric DNA due to the inability of DNA polymerase to 
fully replicate the ends of chromosomes (Hodes, et al 2002, Wright and Shay 2000). The 
induction of telomerase activity can compensate for telomere loss (Hooijberg, et al 2000, 
Plunkett, et al 2005, Rufer, et al 2001). Upon repeated stimulation, cells lose the capacity to 
upregulate telomerase. Consequently, the progressive erosion of telomeres to a critical length 
leads to chromosomal instability and end-to-end chromosome fusion which has consequences 
that include cell-cycle arrest, apoptosis (McEachern, et al 2000) and replicative senescence 
(Akbar, et al 2004, Hodes, et al 2002). During ageing, the number of highly differentiated 
memory T cells that reaches replicative senescence increases (Pawelec, et al 2004). This 
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population of cells would have much reduced telomere length (Akbar, et al 2000) and remain 
functional but with a limited capacity for further clonal expansion following subsequent 
antigenic challenge (Khan, et al 2002, Ouyang, et al 2004). Such an expanded population 
might compete for survival factors with smaller less-frequently or less efficiently stimulated 
memory T cell populations. The accumulation of non-functional antigenic specific cells may 
reduce the available immunological space or other survival factors for T cells of other 
specificities, which are then lost through competition (Khan, et al 2004, Messaoudi, et al 
2004).  
 
The measurement of telomere length has been useful to assess the status and extent of cell 
differentiation of a population of lymphocytes, especially for memory T cells. After an 
immune response resolves, to establish cellular homeostasis, most of the clonally expanded T 
cells are cleared by apoptosis (Akbar, et al 1993a, Akbar, et al 1993b). Nevertheless, some 
antigen-specific T cells are retained and constitute the memory pool. Thus, by measuring the 
T memory subsets telomere length, one is able to predict the SLE disease progression in 
patients. Comparison of telomere lengths of prognostic subgroups v8.1 and v8.2, together 
with the quantifications of markers IL7R and Bcl-2 will be a good indicator of lupus activity 
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